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Abstract 
 
 The integral membrane proteins of neurons and other excitable cells are generally 
resistant to high-resolution structural tools.  In this thesis we present our efforts to probe 
the structure of the agonist-binding site of the nicotinic acetylcholine receptor (nAChR) 
using the tethered agonist approach, which combines chemical synthesis, the nonsense 
suppression methodology for unnatural amino acid incorporation and electrophysiology.  
 
 In Chapter 2, we present the results of incorporating a series of tethered 
quaternary ammonium derivatives of tyrosine into the nAChR using the in vivo nonsense 
suppression methodology for incorporating unnatural amino acids site-specifically.  At 
three sites, a constitutively active receptor results, but the pattern of activation as a 
function of chain length is different.  At position α149, there is a clear preference for a 
three-carbon tether, while at position α93 tethers of 2-5 carbons are comparably 
effective.  At position γ55/δ57, all tethers except the shortest one can activate the 
receptor.  Based on these and other data, a model for the binding site of the receptor can 
be developed by analogy to the acetylcholine esterase crystal structure.   
 
 In Chapter 3, we report evidence that the N-terminal extracellular domain of 
nAChR is closely related to acetylcholine binding protein (AChBP), whose crystal 
structure was solved in May 2001.  Based on the model obtained from docking 
acetylcholine into the structure of AChBP, we designed and incorporated a new tethered 
agonist, lysyl-carbamylcholine.  Incorporation of this tethered agonist at several positions 
 viii
produced constitutively active receptors, with significant activity seen at α192, α193, and 
γ119/δ121.  These results demonstrated that the loop E residue γ119/δ121 on the 
complementary subunit is very near the agonist-binding site.  We also investigated the 
role of an intersubunit hydrogen bond, which was seen in the crystal structure of AChBP.  
Incorporation of tryptophan analogs that abolish the hydrogen bonding abilities slowed 
the desensitization of the receptor, which implied that this hydrogen bond might play a 
key role in the allosteric transitions of desensitization.  
 
 In Chapter 4, we describe our efforts to prepare a short tethered agonist and the 
results of incorporating it into nAChR at α198 by chemical modification of cysteine 
mutants introduced by nonsense suppression methodology.  Methanethiosulphonate 
ethyltrimethylammonium (MTSET) modification resulted in constitutive activity, which 
suggested the closeness of α198 to the agonist-binding site. 
 
 In Chapter 5, methods in molecular biology, electrophysiology and molecular 
docking, and the synthesis of amino acids and dinucleotide dCA-amino acids are 
summarized.  
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1.1  Chemical Approaches to Exploring Molecular Neurobiology 
 
 As an integral part of modern biology, neuroscience has benefited from research 
in all different fields, such as physics, chemistry, mathematics, anatomy, physiology and 
medicine.  Our group has been trying to develop detailed insights into the structure and 
function of the molecules of memory, thought and sensory perception, using chemical 
approaches.  This thesis presents work that is a small portion of these efforts.  We will 
begin with discussion on neuroscience in general and introduce the molecules of the 
brain.  We will then describe some chemical approaches that have been developed and 
used to study these molecules.   
 
The human brain is a remarkably complicated structure (1, 2).  There are
roughly 1012 neurons in a human brain, and there is great diversity among them, with 
perhaps 1,000 different types of neurons.  There are two million miles of axons.  A 
‘typical’ neuron makes connections (synapses) with 103–104 other neurons.  This means 
that there are 1015–1016 synapses in the human brain.  Altogether it makes the human 
brain the most complex structure, natural or artificial, on Earth (3).   
 
Moving toward molecular issues, much of the action occurs at the synapse (4).  
The brain is about cell-cell communication, and the synapse is the gap between two cells 
(Figure 1.1).  Synaptic transmission is mediated by small neurotransmitter molecules 
such as acetylcholine, dopamine and serotonin.  These neurotransmitters are released 
from the presynaptic neuron, traverse the synaptic gap, and are then recognized and 
 3
processed by receptors on the surface of the postsynaptic neuron.  One class of receptors 
is the G protein-coupled receptor class, in which ligand binding leads to activation of G 
proteins and which usually operates in a time frame of seconds (3).  The activated G 
proteins act as second messengers to regulate the metabolism of the cell, as well as by 
directly affecting channel proteins.  These ‘slow’ G protein-coupled receptors play a role 
in modulating synaptic transmission, cell excitability, and sensory systems.  The other 
class of receptors is the ligand-gated ion channels (Figure 1.1), which on ligand binding 
undergo a fast conformational change to open an integral pore within a time frame of 1–
100 ms (3).  The majority of synaptic transmission in the brain is mediated by these ‘fast’ 
receptors.  These receptors, and other neuroproteins such as ion-channels and 
neurotransmitter transporters, are proteins with a tremendous diversity of structure, but a 
few common features. 
       
Figure 1.1.  Schematic of synaptic transmission. A. Two neurons and the synapse 
between them. The red arrow indicates the direction of the action potential.  B. The 
blowup of a synapse. C. Ligand-gated ion channel. 
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First, they are all integral membrane proteins.  That is, they are not membrane-
anchored or structures with just one membrane-spanning segment like the family of 
hormone receptor molecules.  Neuroproteins typically cross the membrane many times, 
some containing 12 or more transmembrane segments.  Often more than half of the 
protein is embedded in the membrane.  Second, many, but not all, neuroproteins are 
multi-subunit systems.  Often four or five individual proteins, each with several 
transmembrane segments, combine to form the functional system.  Because of these 
features, it is in general difficult to accumulate significant quantities of pure, properly 
folded, functional neuroproteins.  They are therefore not amenable to high-resolution 
structural methods, such as x-ray crystallography or NMR spectroscopy.  For some 
systems, very useful low-resolution images are available, but atomic-scale detail is not. 
 
 In the absence of high-resolution structural data, important and fundamental 
insights into the mechanism underlying channel gating have been gained from structure-
function studies at the molecular level.  To do so, we need two tools: a way to modify 
rationally the structures of the neuroreceptors and a means to evaluate the functional 
consequences of the structural changes.   For the latter, modern electrophysiological 
methods have enabled the measurement of the electrical activity of a single cell, even of a 
single ion channel molecule.  As for the way to vary the structure of the neuroproteins, 
traditional site-directed mutagenesis has been a very valuable tool.  However, it is 
restricted to the 20 natural amino acids, and therefore only allows limited structural 
variation.  In order to introduce more chemical probes with diverse structures, chemical 
modification of natural amino acid has been commonly used.  One of the most widely 
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used methods is the substituted-cysteine accessibility method (SCAM).  SCAM is an 
approach to the characterization of channel (5, 6) and binding-site structures (7) that 
probes the environment of any residue by mutating it to cysteine, and by characterizing 
the reaction of the cysteine with sulfhydryl-specific reagents.  Among these reagents, the 
methanethiosulphonates (MTS) are attractive because of their small size and their 
specificity for sulfhydryls (8).  SCAM has been successfully used to identify channel-
lining residues, to determine the potentially different environments of these residues in 
the open and closed states of the channel, to locate selectivity filters and gates, and to 
map the binding sites of channel blockers (9).  In spite of all the success, SCAM has 
several limitations.  First of all, it relies on cysteine mutation and therefore is restricted 
by the extent of the tolerance of the cysteine substitution in the protein.  Second, it is 
limited to those positions that are accessible by the modification reagent.  Furthermore, it 
lacks site-specificity if there are more than one cysteine in the protein.  Finally, there 
might be complications due to side reactions related to the chemical modification. 
 
 In contrast, the nonsense suppression method for incorporating unnatural amino 
acids into proteins (Figure 1.2) has opened up essentially limitless possibilities to conduct 
a wide range of studies into protein structure and function.  For over a decade, a diverse 
array of unnatural amino acids have been incorporated site-specifically into a variety of 
proteins.  The methodology was developed and used in the in vitro translation system by 
Schultz’s group (10) and a few other groups (11).  Our group, in collaboration with Prof. 
Henry Lester, have taken a step further and adapted it into the in vivo translation system 
using the Xenopus oocyte (12, 13) to study the integral membrane proteins that play a 
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central role in molecular neurobiology.  This methodology allowed us to perform more 
systematic structure-function studies when we use unnatural amino acid analogs with 
only subtle changes compared with the natural amino acids (14, 15).  We also 
incorporated unnatural amino acids with more dramatic changes, for example, caged 
tyrosine (16, 17) and biocytin (18).  More remarkably, we even incorporated α-hydroxy 
acids to make the backbone mutation to investigate the change of secondary structure 
during channel gating (19).  In the work presented in this thesis we sought to generalize a 
potentially powerful tool–the tethered agonist approach–for mapping the agonist-binding 
site of the ligand-gated ion channels.  This approach has been applied successfully to 
probe the structure of the agonist-binding site of the prototype ligand-gated ion channel– 
the nicotinic acetylcholine receptor.  We will discuss this in more detail in the following 
chapters. 
 
       
Figure 1.2.  The fundamental protocol for in vivo nonsense suppression methodology for 
incorporating unnatural amino acids site-specifically into proteins.   
 7
1.2 The Nicotinic Acetylcholine Receptor (nAChR) 
 
The nicotinic acetylcholine receptor (nAChR) belongs to a superfamily of ligand-
gated ion channels, which mediate intercellular communication by converting the 
neurotransmitter signal released from the nerve ending into a transmembrane ion flux in 
the postsynaptic neuron or muscle fiber.  The superfamily includes nAChR, 5-
hydroxytrptamine type 3 (5-HT3) receptors, γ-aminobutyric acid type A (GABAA) and 
GABAC receptors, glycine receptors and invertebrate glutamate and histidine receptors 
(8).  All members of the superfamily share sequence homologies as well as structural and 
functional features.     
 
The identification of the nAChR was made possible largely by a few wonders of 
the animal world (20).  First, the electric organ of fish offers both an extremely rich and 
homogeneous source of synaptic material, and single cells (or electroplaques) for 
pharmacological studies.  Second, because of its exquisite selectivity and high affinity, an 
α-toxin from the venom of the snake Bungarus enabled the isolation and purification of 
nAChR from the electric organ (21).  
 
There are both muscle-type and neuronal-type nAChRs.  The muscle receptors 
function at the neuromuscular junction as well as electric organs of certain rays and eels, 
while the neuronal receptors function in the central neural system.  Their physiological 
properties include the activation response to fast application of acetylcholine (ACh) in the 
millisecond timescale resulting in the opening of the ion channel, as well as the slow 
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decrease or even full abolition, of the electrical response referred to as desensitization, 
following a prolonged application of nicotinic agonists and antagonists.  The different 
nAChRs mediate the pharmacological actions of drugs, such as the effects of curare on 
muscle and of nicotine in brain, including addiction in smokers.  The nAChRs are also 
involved in analgesia, enhanced cognition, memory and attention, and therefore also 
serve as the target for a number of promising pharmaceuticals for pain, memory 
enhancement, and the treatment of Alzheimer’s and Parkinson’s diseases (22).  The role 
of desensitization in cholinergic neurotransmission under normal physiological 
conditions is uncertain, but is evident both in some pathological conditions and in 
neurotransmission by other neurotransmitters (23). 
 
The muscle-type nAChR is a heteropentamer of ~300 kDa with a stoichiometry of 
(α1)2β1γδ in electrocytes and fetal muscle and (α1)2β1εδ in adult muscle.  The overall 
shape and dimensions of the complex have been visualized by electron microscopy (EM) 
(Figure 1.3A).  In the embryonic muscle-type nAChR (24), the subunits are arranged 
clockwise in the circular order of αγαβδ, as viewed from the synaptic cleft, like barrel 
staves around a central channel pore with a diameter of ~25 Å at the synaptic entry (25-
27).  Sequence analysis reveals homologies between the nAChR subunits from electric 
organ, skeletal muscle and brain of higher vertebrates, including humans (28).  There are 
12 known types of vertebrate neuronal ACh receptor subunit: α2–α10 and β2–β4.  When 
expressed heterologously, α7, α8 and α9 can form functional homopentamers (29–32).  
By contrast, the α2–α6 and α10 neuronal subunits form functional complexes only when 
coexpressed with β-subunits or with other α-subunits (33–36).   
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         A.                B. 
                  
Figure 1.3.  The structure of nAChR. A. The overall layout of the nAChR, based on the 
4.6 Å resolution structure by cryo-electron microscopy studies (26, 27). (Figure adapted 
from ref. (37).) B. The transmembrane topology of each subunit. The four transmembrane 
regions are indicated as M1, M2, M3, and M4, respectively.  
 
All nAChR subunits share a similar hydropathy profile (Figure 1.3B), with a large 
N-terminal hydrophilic domain (comprising ~210 amino acids) that faces the synaptic 
cleft and carries the ACh-binding site, four ~20-amino acid hydrophobic transmembrane 
stretches (the second of which, M2, lines the ion channel), and a hydrophilic cytoplasmic 
loop that contains the phosphorylation sites and is involved in receptor biosynthesis, 
assembly, transport, clustering, anchoring, and modulation.   
 
Attempts to solve the entire structure of nAChR failed, for the reasons discussed 
earlier.  Structural studies were thus limited to electron microscopy (EM) down to 4.6 Å 
resolution (27) and to the recombinant N-terminal synaptic domain of nAChR.  Circular 
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dichroism revealed a high content of β-sheet structure in the isolated extracellular domain 
of the α1-subunit of the mouse muscle receptor (38), a finding consistent with recent EM 
images that revealed tunnels in the α1-subunit N-terminal domain of Torpedo receptor 
that were framed by seven twisted β strands running approximately perpendicular to the 
membrane plane (27).  In addition, secondary structure predictions suggested an 
immunoglobulin-like folding, almost exclusively of β sheets, for the N-terminal domain 
of the nicotinic receptor (39).  High-resolution data at the atomic level are now available 
for ACh binding protein (AChBP) (see section 1.4).  
 
The residues located at the interface are not well conserved among nAChRs and 
probably contribute to the diversity of subunit combinations.  By contrast, specific 
interactions (e.g., hydrophobic, polar, hydrogen bonds) have to be at least partially 
conserved to mediate common features of the allosteric transitions.  The nAChRs are 
allosteric, in that they are oligomeric, contain multiple agonist-binding sites, 
noncompetitive antagonist sites, and gates that interact at a distance (~20-40 Å between 
the binding sites and the ion channel based on fluorescence transfer measurements (40)) 
through changes in the quaternary structure of the receptor.  In response to ACh, single 
nAChR molecules undergo a conformational transition to an open channel low-affinity 
state, associated with slower modulatory transitions to (or from) desensitized, closed and 
high-affinity states.  Four functional states have been described in nAChRs (Figure 1.4): 
the resting (closed) state (R), the active open state (O), the fast-onset desensitized 
(closed) state (I), and the slow-onset desensitized (closed) state (D) (41-48).  The resting 
state is the most stable state in the absence of agonist, and the slow-onset desensitized 
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state is the most stable state in the presence of agonist.  The open state and the fast-onset 
desensitized state are metastable states, in that their concentrations rise transiently and 
reach a very low value at equilibrium.  The nAChRs also open, albeit rarely, and 
desensitize in the absence of agonist.  Many models have been developed to fit the 
kinetics of agonist binding, channel opening and closing, and desensitization.  One of 
them is the Monod-Wyman-Changeux (MWC) model of allosteric interactions (49, 50).  
The MWC theory has been extended to accommodate multiple functional states and 
quasi-symmetry (46, 48)  since most nAChRs are asymmetrical heteromers.   
 
 
Figure 1.4.  Transitions between the four states of the nAChRs.  It is assumed that the two 
agonist-binding sites are different. The subscripts indicate the state of occupation of the 
sites: 00, unoccupied; 01 or 10, singly occupied; 11, doubly occupied.  Heavy arrows 
indicate a principal reaction pathway.  (Figure adopted from Ref. 8.) 
 
Although the requirement for a conformational change that links agonist binding 
to the opening of the ion channel portion of the receptor (gating) has been obvious, the 
details have remained elusive.  The allosteric transitions of the protein underlying the 
physiological ACh-evoked activation and desensitization possibly involve movement of 
the extracellular domain of each subunit, linked to a reorganization of the transmembrane 
domain responsible for channel gating.  One of the structural elements in the extracellular 
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domain that is thought to be involved in gating is a disulfide bond.  The nAChR family is 
also known as Cys-loop receptors because all family subunits contain a pair of disulfide-
bonded cysteines (128 and 142 in nAChR α1) that are separated by 13 residues in their 
amino-terminal extracellular domains.  This disulphide bond is also called the ‘signature 
loop’ that defines this group of proteins.  For the gating mechanism associated with the 
transmembrane domains, two competing models have been proposed.  In one model, 
transmembrane helices are postulated to rotate as rigid bodies, removing a leucine side 
chain from a blocking position and opening the channel (51).  In a competing proposal, 
the transmembrane segments M1 and M2 slide past each other and convert from a 
relatively unstructured form to a well-defined α helix (52, 53).  
 
Although the structures of the membrane and cytoplasmic domains are less well 
determined compared with the extracellular domain, the channel lining and the 
determinants of selectivity have been mapped.  The location and structure of the gates 
remain to be established.  Studies by EM (26), spectroscopic (54, 55) and computational 
(39) methods as well as chemical labeling and mutagenesis indicate that the membrane-
spanning segments are not completely α-helical, as originally predicted, but seem to be a 
mixture of α-helix, β-strand, and irregular secondary structures (8).  The approximate 
arrangement of the membrane-spanning segments is known: M2 and part of M1 line the 
central lumen, and M3 and M4 are in contact with lipid.  Specific M2 residues (2′, 6′ and 
9′ counting from the cytoplasmic, amino-terminal end of M2) that line the channel have 
been identified by photolabeling with noncompetitive inhibitors (56, 57).  SCAM has also 
been used to identify residues that are exposed to water, which in the membrane domain 
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include the channel lining residues (5, 58-61).  It should be noted that the picture is 
dynamic.  Many residues that line the channel, that are associated with the gates and even 
with the protein–lipid interface, are in different environments in the different functional 
states. 
 
Except for an anion-selective invertebrate nAChR (61), all known nAChRs are 
cation selective, as are 5-HT3 receptors.  All other Cys-loop receptors are anion selective.  
Cation-selective nAChRs are permeable to monovalent and divalent cations.  In muscle-
type nAChR, the ratio of permeabilities PCa/PNa is ~0.2 (62).  A short (~6 Å in length) 
narrow (7-8 Å in diameter) section, which is at the cytoplasmic end of the channel, 
selects for ion charge and size, and determines conductances (63-67).  This region also 
contains the resting gate (52, 68).  The conductance ratios were most sensitive to 
mutations of polar residues at the 2′ position (63, 65), which is therefore likely to be in 
the narrowest part of the channel and to constitute part of the selectivity filter.  
 
1.3 The Agonist-Binding Site of nAChR 
 
The agonist-binding sites of the nAChR are located at subunit interfaces (21).  
The muscle-type receptor has two distinct ACh-binding sites (located at interfaces 
between the α and γ, and the α and δ, subunits).  Photoaffinity labeling and mutagenesis 
studies have identified a number of residues as being crucial for ligand binding.  Affinity 
labeling experiments performed with a series of competitive antagonists of different 
chemical structures show that all probes label primarily the α1 subunits, and to a lesser 
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extent the γ and δ subunits.  This supports an asymmetric location of the binding site with 
respect to the interface.  It is thus proposed that the α1 subunits form the ‘principal 
component,’ while γ or δ subunits contribute to the ‘complementary component’ of the 
nicotinic binding site (21).  The principal part is composed of α-subunit residues– 
contributing to the so-called ‘loops’ A (W86 and Y93) (69), B (W149 and Y151) (70) 
and C (Y190, C192, C193 and Y198) (71, 72), whereas the neighboring subunit residues 
–contributing to the ‘loops’ D (γW55/δW57) (73), E (γL109/δL111 and γY111/δR113) 
(74, 75) and F (γD174/δD180) (76), form the complementary part of the binding pocket 
(Figure 1.5).  In all the photoaffinity labeling studies that identified the above residues, 
different agonists and antagonists photolabeled various residues to different extents, some 
with significant amounts of labeling, some with weak labeling.  Results from mutagenesis 
studies are consistent with the findings of the photoaffinity labeling studies.  Mutations of 
the loops A–C residues affected the binding of both agonists and competitive antagonists 
(77-80).  Mutations of the loop D residues affected agonist binding and gating, but had 
little effect on antagonist binding (81).  By contrast, mutations of loop E residues only 
affected competitive antagonist binding, but not agonist binding or gating (75, 82, 83).  
These results are consistent with the notion that the loops A–D are the main component 
of the agonist-binding site, while the loops E and F are less important and more remote.  
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Figure 1.5.  The structure of nAChR with a blowup of the agonist-binding site that was 
mapped based on biochemical studies.  The one at the α and γ subunit interface is shown, 
there is an equivalent one at the α and δ subunit interface.  (Image adapted from ref. 27.) 
 
All the residues mentioned above, especially those in loops A-D, are considered 
the key residues that contribute to ligand binding.  Among them, most of them are 
aromatic residues–tyrosine or tryptophan.  This has led us to propose that cation-π 
interactions might be important in binding the positively charged quaternary ammonium 
group of ACh.  Extensive studies by our group have established that one of the aromatic 
residues–αTrp 149–is the cation-π site (14).  We will discuss this in more detail in 
Chapter 2.  In our earlier studies we investigated the roles played by three tyrosine 
residues–α93, α190, and α198–by unnatural amino acid mutagenesis, we found some 
interesting results but no indication of a cation-π interaction (12, 15).  We found that the 
hydroxy group of αTyr 93 plays a crucial role, and a variety of tyrosine analogues are 
functional at αTyr 198, while αTyr 190 is an especially delicate site. 
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 Besides the aromatic residues, there are a pair of adjacent cysteines, αCys192 and 
αCys 193, which form a highly unusual disulfide bond (84).  This disulfide bond is 
characteristic of all nAChR α-subunits and absent in non-α subunits.  A crosslinking 
experiment with a 9 Å bifunctional reagent reacting with the reduced αCys192-193 not 
only identified a carboxylate residue δAsp 180–the only negatively charged residue that 
has been shown to participate agonist binding–but also provided information on the 
distance between the two subunits within the agonist-binding site. 
 
In the muscle-type nAChR, the two agonist-binding sites are not equivalent.  In 
heterologously expressed combinations of subunits, the complex of α- and γ-subunits had 
a higher affinity for competitive antagonists, whereas the complex of α- and δ-subunits 
had a higher affinity for agonists (85).  In complete receptor complexes, the two sites also 
bind agonists with different affinity (86).  In addition, nAChRs are known for their 
pharmacological diversity.  Different types of receptors bind different agonists or 
antagonists with different affinities.  All the biochemical studies support the notion that 
variable residues located in the vicinity of the affinity labeled amino acids are the major 
elements contributing to the pharmacological diversity of the nAChRs (21).  The 
emerging picture is that the binding site consists of a conserved core of aromatic residues, 
and that variable amino acids neighboring these positions, as well as several amino acids 
from the nonconserved loops E and F, confer on each receptor subtype its individual 
pharmacological properties.  
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Although there have been plenty of biochemical and electrophysiological studies 
on nAChR, the structure at atomic resolution has been missing.  Recently, a high 
resolution structure of a protein that is homologous to the extracellular domain of the 
receptor has revealed the binding sites and subunit interfaces in great detail.  
 
1.4 The Crystal Structure of Acetylcholine Binding Protein (AChBP)  
 
 Our knowledge of the structure of the nAChR, especially the extracellular 
domain, has been greatly advanced by the solution of the high-resolution structure of a 
snail ACh-binding protein (AChBP).  In May 2001, Sixma and coworkers reported the 
discovery, cloning, physiological characterization, and crystal structure of AChBP (87, 
88).  AChBP is a small soluble protein that is stored and produced in snail glia cells and 
secreted in an ACh-dependent manner into cholinergic synapses, where it acts as a 
protein buffer and modulates synaptic transmission by binding ACh.  AChBP binds 
agonists and competitive antagonists of the nAChR, including ACh, nicotine, epibatidine, 
(+)-tubocurarine and α-bungarotoxin, resembling the α7-subtype of nAChR, albeit with a 
higher affinity for most of the ligands.  AChBP is homologous to the extracellular 
domain of the nAChR–the region that contains the agonist-binding site.  The structure of 
AChBP reveals in great detail the nature of the ligand binding domains and the subunit 
interfaces of the nAChR.  Moreover, the structure is completely consistent with 40 years 
of biochemical studies of the agonist-binding site of the nAChR (see 3.1 for more 
details). 
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AChBP forms a homopentamer.  Each subunit contains 210 amino acids and is 
20-24% identical to the aligned sequences of the amino-terminal, extracellular domain of 
the nAChR subunits.  However, AChBP lacks the transmembrane and intracellular 
domains present in the ligand-gated ion channels superfamily.  Nearly all the residues 
that are conserved within the nAChR family are also present in AChBP.  The 
characteristic disulphide bond referred to as the Cys-loop is present in the AChBP 
subunit, but there are only 12 intervening residues in place of the 13 that are found in the 
nAChR subunits.  These residues are almost all different in AChBP compared with 
nAChR subunits.  The Cys-loop consists of highly conserved hydrophobic residues in the 
nAChR family and is hypothesized to interact with some channel-forming elements.  It is 
possible that this conserved loop is involved in coupling the extracellular domain of 
nAChR to the membrane region that is absent in the AChBP.  In addition, the occurrence 
of the hydrophilic amino acids in the AChBP Cys-loop together with the presence of 
glycosylation sites, might be sufficient to yield a soluble homopentameric complex. 
 
The crystal structure of AChBP reveals an oligomer of five identical asymmetric 
subunits arranged in an anticlockwise manner along the fivefold axis (Figure 1.6A).  In 
three dimensions, the AChBP is 80 Å in diameter, 62 Å in height, with an axial channel 
that is ~18 Å in diameter.  The size and shape of AChBP is consistent with cryo-electron 
microscopy data for the N-terminal domain of Torpedo nAChR (26, 27).  
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Figure 1.6.  The structure of AChBP.  A. The pentameric AChBP, viewed along the five-
fold axis.  Subunits are labeled anticlockwise in different colors, with A-B forming the 
plus and minus interface side, with the principal and complementary ligand-binding sites, 
respectively (ball-and-stick representation).  B. Viewing the AChBP pentamer 
perpendicular to the five fold axis.  The equatorially located ligand-binding site (ball-and-
stick representation) is highlighted only in the A (yellow)-B (blue) interface.  (Figures 
adapted from ref. 81.) 
 
Each subunit of AChBP comprises an N-terminal α helix, two short 310 helices 
and a core of ten β strands folded into a twisted β sandwich.  The β strands are arranged 
with a uniquely modified immunoglobulin-like topology.  The two twisted β sheets of the 
β sandwich are connected by the Cys-loop, which is close to the subunit carboxyl 
terminus at the ‘bottom’ of the cylindrical complex. In nAChR, the Cys-loop and the 
bottom of the complex are close to the extracellular surface of the membrane.  The amino 
terminus of the AChBP subunit is at the opposite end of the cylinder (the ‘top’), placing 
the amino termini of the Cys-loop receptor subunits farthest from the membrane.  The 
main immunogenic region (MIR) of the ACh receptor α1-subunit aligns with AChBP 
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residues at the top of the cylinder.  The secondary structure of the AChBP subunit closely 
resembles that predicted for the extracellular domain of the ACh receptor subunits (39).  
 
The subunit interfaces are of considerable interest as they might play a crucial 
role in allosteric transitions.  The plus side of the interface (Figure 1.6B) is framed 
essentially by loops, whereas the minus side mostly presents secondary structure 
elements. The residues located at the interface (88) are not well conserved among 
nAChRs and probably contribute to the diversity of subunit combinations.  Hydrophobic 
residues in AChBP are essentially located inside the subunit interface whereas polar 
residues are exposed to the outside where they promote oligomerization. 
   
 In summary, the structure and function of the nAChR is becoming more and more 
clealy understood.  In particular, the high-resolution structure of AChBP has brought 
tremendous insights to the knowledge of the receptor, especially the N-terminal 
extracellular domain which contains the agonist-binding site.  In this thesis, we present 
our efforts to probe the structure of the agonist-binding site of the mouse muscle nAChR 
using the tethered agonist approach, which combines chemical synthesis, unnatural amino 
acid mutagenesis, electrophysiology, and computer modeling.  On one hand, our results 
have been confirmed by the structural data of AChBP.  On the other hand, our results 
have provided further evidence that AChBP is closely related to the extracellular domain 
of nAChR.  Altogether our results provide detailed information on ACh binding, based 
on which the picture of how ACh binds to the agonist-binding site of nAChR is 
emerging.  
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Chapter 2 
 
 
 
Mapping the Agonist-Binding Site of the nAChR by Tethered Agonists–
Identification of Residues Contributing to the Binding of the 
Quaternary Ammonium Group of Acetylcholine 
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2.1  Introduction 
 
 As discussed in Chapter 1, a large number of aromatic amino acids were 
identified as contributing to the agonist-binding site of the nAChR.  This led us to 
propose that a cation-π interaction may be important in binding the quaternary 
ammonium group of ACh (1).  The cation-π interaction is a general noncovalent binding 
force, in which the face of an aromatic ring provides a region of negative electrostatic 
potential that can bind cations with considerable strength (2, 3).  In a biological context, it 
is the aromatic side chains of Phe, Tyr, and Trp that can be expected to be involved in 
cation-π interactions, and a large body of evidence indicates a prominent role for cation-π 
interactions in structural biology in general (2, 4, 5).  The physical underpinnings of the 
cation-π interaction are now well understood, so that one can use ab initio quantum 
mechanical calculations on small model systems to predict with some confidence how 
modifications of an aromatic system should affect its cation-π binding ability (6, 7).  This 
knowledge, combined with extensions to site-directed mutagenesis for in vivo unnatural 
amino acid incorporation (8-11) allows the systematic evaluation of potential cation-π 
binding sites. 
 
Then the question is which, if any, of the aromatic residues involved in agonist 
binding undergoes a direct cation-π interaction with the agonist.  Previously, we used 
unnatural amino acid mutagenesis to evaluate three conserved tyrosines at the agonist-
binding site (Figure 1.5) (8, 12), with no results that suggested a cation-π interaction.  
However, theoretical studies of the cation-π interaction (7) and surveys of protein 
 30
structures (3, 5) clearly indicate that, of the natural amino acids, Trp presents the most 
potent cation-π binding site.  We then studied the four different tryptophans implicated in 
ACh binding–α86, α149, α184, and γ55/δ57.  Using nonsense codon suppression 
procedures, we incorporated and evaluated electrophysiologically a series of Trp 
derivatives (13, 14).  The most intriguing data came from studies of the fluorinated Trp 
derivatives.  The strongly electron-withdrawing fluoro substituent substantially weakens 
the cation-π interaction, while fluorine is generally considered to be a substituent that 
provides a negligible steric perturbation.  Beginning with 5-F-Trp and moving on to di-, 
tri-, and tetrafluoro derivatives produces a series of closely related compounds with 
substantial electronic but minimal steric changes.  Progressive fluorination at position 
α149 leads to a systematic increase in EC50.  As shown in Figure 2.1, there is a 
compelling correlation between: a) ab initio quantum mechanical predictions of cation-π 
binding abilities; and b) EC50 values for ACh at the receptor for a series of tryptophan 
derivatives, which were incorporated into the receptor using the in vivo nonsense 
suppression method for unnatural amino acid incorporation.   
           
Figure 2.1.  Plot of log [EC50/EC50 (wild type)] vs. quantitative cation-π binding ability 
at α149 for the fluorinated tryptophans. 
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Such a correlation is seen at one, and only one, of the aromatic residues–
tryptophan-149 of the α subunit.  This finding indicates that, on binding, the cationic, 
quaternary ammonium group of ACh makes van der Waals contact with the indole side 
chain of α tryptophan-149, providing the most precise structural information to date on 
this receptor.  Note that the maximum in cation-π binding occurs over the six-membered 
ring of Trp (2, 6), and the calculated cation-π binding energies involve such a geometry, 
so the quaternary ammonium of ACh must be positioned over the 6-ring of αTrp 149 
(Figure 2.2).  This model suggests that any means of positioning a quaternary ammonium 
in close proximity to αTrp 149 might produce an active receptor.  Thus, the unnatural 
amino acid Tyr-O3Q (Tyr-O-(CH2)3-N(CH3) 3+, see Figure 2.2) was prepared and 
incorporated at this position.  The quaternary ammonium group in the side chain of Tyr-
O3Q was meant to mimic the analogous functional group in ACh.  Modeling clearly 
shows that the quaternary ammonium of Tyr-O3Q can achieve the same position as that 
proposed in the binding of ACh.  Indeed, incorporation of Tyr-O3Q at position α149 
produces a constitutively active receptor, resulting in nicotinic receptor current even in 
the absence of ACh.  
 
        
CH2
O
Me3N
N
H
Me3N
O C(O)CH3
CH2
 
Figure 2.2.  (Left) Schematic of the quaternary ammonium of ACh positioned over the 6-
ring of αTrp 149.  (Right) Structure of Tyr-O3Q, showing that the tethered quaternary 
ammonium can be positioned in roughly the same location as the quaternary ammonium 
of ACh. 
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The tethered agonist strategy has a distinguished history with the nAChR.  In 
pioneering experiments, tethered agonists were introduced into the nAChR using 
chemical modification of Cys residues created by reduction of the Cys 192-193 disulfide 
bond (see Figure 1.5), producing a constitutively active receptor (15, 16).  Very recently, 
Cohen expanded on this methodology by introducing Cys residues using site-directed 
mutagenesis and then reacting the mutants with various MTS reagents (17).  We will 
discuss these results below.  The unnatural amino acid mutagenesis approach offers an 
alternative and in some ways preferable strategy for introducing tethered agonists.  Since 
the approach does not rely on cysteine modification, the tether can be incorporated at 
many different positions, including sites where the Cys mutant cannot produce functional 
receptors, and sites that are not accessible to external reagents, as might be expected at a 
potentially buried agonist-binding site.  This strategy also removes ambiguities in tether 
location that can arise if more than one cysteine is present in the molecule and allows a 
wider variation in functionality.  In addition, agonist-like functionalities are introduced 
directly into the receptor, eliminating possibly deleterious side reactions associated with 
chemical modification strategies. 
 
In this chapter, we presents our efforts to expand upon our initial observations 
concerning a tethered agonist in several ways, and thereby establish the generality of the 
approach. We show that varying the tether length produces a variation in tethered agonist 
efficiency; and we reveal two other sites–αTyr 93 and γTrp 55/δ Trp 57–where the 
tethered agonist strategy is successful (18).  We also discuss the results of incorporation 
of an isosteric but electronically neutral analog of Tyr-O3Q termed Tyr-O3tBu (Figure 
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2.6), in which the quaternary ammonium is replaced by a tert-butyl group.  With these 
new findings, a more advanced, but still speculative, model for the nAChR agonist- 
binding site can be developed (18). 
 
2.2  Incorporation of Tyr-OnQ into the nAChR 
 
We attempted incorporation of the series of quaternary ammonium derivatives of 
tyrosine, Tyr-OnQ (n= 2, 3, 4, and 5) (see Figure 2.5 for structures), at several positions 
around the agonist-binding sites of the nAChR, including: αTrp 86, αTyr 93, αTrp 149, 
αTrp 184, αTyr 190, αCys 192, αCys 193, αPro 194, αTyr 198, γTrp 55/δTrp 57, and 
γAsp 174/δAsp 180.  Thus, at least one site was probed on each of the five ‘loops’ (A– D, 
F) that have been proposed to define the ACh-binding site (Figure 1.5).  Given the 
stoichiometry of the receptor, suppression in an α subunit incorporates two copies of the 
modified side chain, one associated with each of the two agonist-binding sites of the 
receptor.  For sites in non-α subunits, we always made two mutations–one in γ and one in 
the analogous site in δ–so that both agonist-binding sites are comparably perturbed.  
Mutant proteins were expressed in Xenopus oocytes and whole-cell currents were 
measured using two-electrode voltage-clamp electrophysiology (9, 12, 19). 
 
The hallmark of a successful experiment is the observation of large standing 
currents in Xenopus oocytes expressing the mutant channel in the absence of added ACh  
(Figure 2.3, identified as a).  The standing currents are reduced in the presence of the 
open-channel blocker 8-(N,N-diethylamino)octyl 3,4,5-trimethoxybenzoate (TMB-8).  
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This establishes that the observed current is due to a nAChR, rather than a nonspecific 
basal current in the oocyte.  Note that TMB-8 blocks the channel by binding to the open 
state of the receptor in the pore region at a site that is quite far removed from the agonist-
binding site.  As such, the mutations we are introducing should not impact the ability of 
TMB-8 to block constitutive current.   
     
Figure 2.3.  Representative recording trace (blue) of voltage-clamp currents for an 
individual oocyte expressing mutant nAChR with Tyr-O3Q incorporated at α149.  The 
red horizontal bars indicate bath application of ACh (5 µM) and TMB-8 (5 µM).  a:  
standing current due to constitutively active nAChR; b: standing current that is blocked 
by TMB-8; c: ACh-induced current. 
 
In earlier studies involving Tyr-O3Q at position αTrp 149, we also used blockade 
of the standing current by α-bungarotoxin as well as channel blockers such as QX-314 
and NMDG; dose-dependent antagonism by curare; and single-channel measurements to 
associate the standing current with the nAChR (13, 14).  In addition, we showed that 
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prolonged exposure (>3 min) to high ACh concentrations led to desensitization of both 
the standing currents (Figure 2.4), further evidence that the response arises directly from 
nAChR.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4.  The standing current is partially occluded by additional ACh.  During the 
first application of TMB-8 (5 µM), the standing outward current was reduced reversibly 
to nearly zero.  ACh (25 µM) was then added, inducing an inward current that 
desensitized.  During the desensitization phase, the standing current was reduced.  TMB-
8 was added again during the desensitization phase.  The TMB-8 deflection reached the 
former plateau level rather than producing a net outward current.  These interactions 
show that ACh desensitizes the conductance mechanism that produces the standing 
current; therefore the standing current is produced by functional nAChR. 
 
In the present work, constitutively active receptors were observed at only three of 
the sites evaluated–αTrp 149, αTyr 93, and γTrp 55/δTrp 57.  At the other sites, the 
typical outcome was that no constitutive current that could be blocked by TMB-8 was 
seen.  In some cases, very small, TMB-8 blockable constitutive currents were seen, but 
only when the expression level for the receptor was especially high, as indicated by large 
-500nA 
TMB-8
0n
ACh
TMB-8
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ACh-induced currents (see Appendix I).  We are reluctant to interpret such small 
currents.  Concerning these other sites, it is, in general, risky to interpret ‘failed’ nonsense 
suppression experiments.  It could well be that the unnatural amino acid failed to 
incorporate into the protein at the ribosome.  Alternatively, ‘failure’ could mean that the 
unnatural amino acid was incorporated at the ribosome, but after incorporation the mutant 
protein failed in folding, or assembly, and/or transport to the cell membrane.  Or perhaps 
receptors containing the tethered agonists were expressed on the surface of the oocyte, 
but the mutant protein is nonfunctional.  Generally it is difficult to distinguish among 
these possibilities, and for the remainder of this work we will focus on the three sites that 
produced constitutively active receptors. 
 
In addition to the channel blocker TMB-8, receptors were treated with the natural 
agonist acetylcholine, and in all cases such treatment led to an increase in current.  This 
establishes that a tethered quaternary ammonium group is a fairly weak agonist, a so-
called partial agonist, meaning that full potency is never reached with the tether alone.  
Our earlier study (13) showed that, as expected, single channel conductance for the 
tethered system is identical to that of the native receptor, so it is the open probability that 
does not reach optimal values.  Further supporting this view, standing currents are only 
observed when a mutation of Leu 262 (conventionally referred to as Leu 9’) to Ser is 
introduced into the channel (M2) region of the β subunit.  Such a mutation is quite far 
removed from the agonist-binding site and is well established to facilitate channel 
opening (13, 20, 21).   
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Figure 2.3 defines the key parameters for evaluating tethered agonist experiments.  
It begins with a standing current that by convention is considered negative.  For the 
particular oocyte shown, the value of the standing current (a) was -1200 nA.  Application 
of 5 µM ACh causes a downward deflection, indicating an increase in current, and the 
magnitude of the ACh induced current is c.  After removal of ACh and reestablishment of 
a (slightly shifted) baseline, TMB-8 is added, and the drop in current is labeled b.  
Numerically, b is equal to the difference between the standing current and the current in 
the presence of TMB-8.  As a gauge of the effectiveness of a given tether in opening the 
receptor, we use the ratio of the constitutive current that is blocked by TMB-8 to the 
ACh-induced current (Figure 4, b/c).  This measures the extent to which the tethered 
agonist opens the receptor relative to the presumed maximal response as seen with added 
ACh.  Using this ratio minimizes complications due to variations in the expression level 
of the receptors in Xenopus oocytes.  The larger the b/c ratio, the more effective the 
tethered agonist.  We appreciate that this is an imperfect measure of the effectiveness of a 
tethered agonist, but we consider it to be a useful qualitative guideline.  No quantitative 
significance is given to the ratios.  Figure 2.5 summarizes the results of incorporation of 
Tyr-OnQ into the nAChR at the three sites. 
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Figure 2.5.  Tethered agonist relative efficiencies for Tyr-OnQ as a function of n (the 
number of methylene groups in the side chain) at positions α149, α93, and γ55/δ57.  
*The value is measured as ratio of constitutive current that is blocked by TMB-8 to ACh-
induced current (b/c per Figure 2.3).  Data shown are for an ACh concentration of 25 
µM, although comparable results are seen with other concentrations.   
 
2.3  Incorporation of an Isosteric, Neutral Tether 
 
While Tyr-OnQ was designed to deliver a mimic of a key aspect of ACh, the 
quaternary ammonium group, it remained possible that the agonism seen in these 
experiments is due to some less specific effect, such as a simple steric disruption of the 
agonist-binding site.  To address this concern we prepared the isosteric compound of Tyr-
O3Q, where the quaternary ammonium is substituted by a tert-butyl group (Figure 2.6).  
 
 39
     
 
Figure 2.6.  Structure of Tyr-O3Q and Tyr-O3tBu. 
 
We incorporated Tyr-O3tBu at α149, α93, and γ55/δ57 sites.  We found that 
incorporation of Tyr-O3tBu at α93 and γ55/δ57 does produce constitutively active 
receptors.  In most cases Tyr-O3tBu is less effective than Tyr-O3Q, based on both the 
magnitude of the constitutive currents (data not shown) and the ratio of the TMB-8-
blocked current to ACh-induced current (Figure 2.7).  
 
Figure 2.7.  Results of incorporation of Tyr-O3tBu compared with that of Tyr-O3Q at 
three sites of nAChR.  A. Constitutive current.  B. The value plotted is the ratio of 
constitutive current that is blocked by TMB-8 (10 µM) to ACh (25 µM)-induced current, 
b/c in Figure 2.3. 
 
 40
Upon attempted incorporation of Tyr-O3tBu at α149, the site at which Tyr-O3Q 
is most effective, no constitutive current is observed.  In addition, only very small 
currents are observed upon application of ACh.  This result could imply that receptors 
containing Tyr-O3tBu at α149 are not constitutively active and cannot be activated by 
ACh because the tert-butyl compound is obstructing the binding site.  Alternatively, the 
results could signal that there are no receptors expressed on the surface of the oocytes.  
To discriminate between these two possibilities, further investigations were undertaken to 
determine whether nAChR are indeed expressed on the surface of the oocytes in the Tyr-
O3tBu incorporation experiments.  Using either binding studies on intact oocytes with 
[125I]-bungarotoxin (Figure 2.8) or Western blot analyses of oocyte membranes (Figure 
2.9), we found that indeed more nAChR are expressed on the surface of the oocyte when 
Tyr-O3Q is incorporated than Tyr-O3tBu.  In fact, the apparent expression of Tyr-O3tBu 
is generally not above background levels seen in control suppression experiments. 
        
Figure 2.8.  Binding of nAChR by 125I-α-bungarotoxin measured by γ counter.  (See 
Chapter 5 for experimental detail.)  Q3, tBu and 5-Me-W are mutant receptors with Tyr-
O3Q, Tyr-O3tBu and 5-methyl Trp (giving similar signal as wild type residue-Trp) 
incorporated at αTrp 149, respectively; dCA, unacylated tRNA was used instead of 
aminoacyl-tRNA; H2O, oocytes were injected with H2O only.  
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       A.              B.
          
Figure 2.9.  Western blots of nAChR.  A. Sample prepared by stripping oocyte 
membrane.  B. Biotinylation of surface proteins.  (See Chapter 5 for experimental detail.) 
MW, molecular weight standard; αHA, α subunit with HA epitope; Q3 and tBu, mutant 
receptors with Tyr-O3Q and Tyr-O3tBu; dCA, unacylated tRNA was used instead of 
aminoacyl-tRNA; in vitro αHA, in vitro translation of α subunit with HA epitope using 
wheat germ. 
 
2.4  Discussion 
 
The present study shows that the tethered agonist approach, as implemented by 
the in vivo nonsense suppression methodology, is a general tool that can provide valuable 
information about the agonist-binding site of a neuroreceptor.  Tethered agonists at three 
different sites give constitutively active receptors.  Variations in tether length can 
discriminate among the different sites.  In the particular case of the nAChR, we believe 
the results have significant implications for efforts to understand the structure of this 
complex protein. 
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In our preliminary report only Tyr-O3Q at position α149 was studied.  We now 
find that tether length significantly influences the effectiveness of the agonist at this 
position.  As shown in Figure 2.5, Tyr-O3Q represents the most effective chain length.  
Both longer and shorter tethers are significantly less effective at inducing current–Tyr-
O5Q produced no measurable constitutive current.  We interpret this, in part, as a 
conformational effect.  We concluded from our earlier studies that when ACh binds to the 
nAChR, the quaternary ammonium group makes van der Waals contact with the six-
membered ring of αTrp 149 through a cation-π interaction (13). When Tyr-OnQ is 
incorporated at α149, its aromatic ring aligns with the five-membered ring of the wild- 
type Trp.  Note that an aromatic group is part of the Tyr-OnQ motif primarily for 
synthetic reasons.  It is not anticipated that a cation-π interaction is involved between the 
tethered quaternary ammonium group and the aromatic ring of the side chain.  The tether 
of Tyr-OnQ must curve around to position the quaternary ammonium above the site 
where the six-membered ring of the natural Trp would be.  Modeling indicates that this is 
unlikely for a 2-carbon tether, but is possible for tethers of length ≥ 3.  Perhaps the tethers 
of Tyr-OnQ are too long when n = 4 or 5, inflicting adverse steric interactions when 
positioning the quaternary ammonium appropriately.  The strong preference for a 3-
carbon tether at position α149 suggests a fairly strict geometric requirement for achieving 
the maximum in constitutive activation. 
 
We have also established that incorporation of tethered agonists at two other sites 
creates a constitutively active receptor.  One of these sites is α93.  Previous photoaffinity 
and site-directed mutagenesis studies have suggested that αTyr 93 is near the agonist- 
 43
binding site (22, 23).  Our earlier evaluation of this residue using unnatural amino acid 
mutagenesis indicated that the OH of the Tyr forms an important hydrogen bond that 
affects agonist binding; however, ACh is not the acceptor of this hydrogen bond (12).  As 
shown in Figure 2.5, Tyr-OnQ with n = 2 to 5 are comparably effective at α93, in 
contrast to the results for α149.  
 
The other site where tethered agonists lead to a constitutively active receptor is γ 
Trp 55/δTrp 57.  All the tethers with long chains ( ≥ 3 carbons) are modestly effective at 
this site.  This suggests that γ55/δ57 must be fairly near the agonist-binding site. 
However, it is likely to be further away than αTrp 149 and αTyr 93, since the shortest 
tether is not effective.  In fact, all tethers are less effective at γTrp 55/δTrp 57 than at the 
other sites. 
 
We note that the constitutive currents (Figure 2.3, a) are consistently larger when 
Tyr-OnQ is incorporated at α149 than at α93 and γ55/δ57 (data not shown).  This is not 
simply because the receptor expresses more efficiently with the tether at α149, since the 
ratio of TMB-8-blocked current to ACh-induced current shows the same trends.  
Apparently, Tyr-OnQ is able to position the quaternary ammonium more precisely and/or 
with less overall disruption of the receptor when it is delivered via α149 than α93 or 
γ55/δ57.  
 
Interesting results are seen with Tyr-O3tBu, a tether that is isosteric to but lacks 
the positive charge of Tyr-O3Q.  No constitutively active or ACh-induced currents are 
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seen from efforts to incorporate Tyr-O3tBu at α149.  We noted above the challenges of 
interpreting negative results from nonsense suppression experiments.  However, at the 
Trp α149 site we know that  (a) nonsense suppression can be quite efficient if different 
unnatural amino acids are employed; (b) a sterically very similar residue (Tyr-O3Q) 
incorporates efficiently; and (c) the desired residue, Tyr-O3tBu, does incorporate at other 
sites (see below) and therefore is compatible with the ribosomal machinery.  Although 
not completely conclusive, efforts to determine whether the receptor containing Tyr-
O3tBu was successfully synthesized, assembled, and transported to the surface suggest 
that it was not.  For the reasons enumerated above, we consider it unlikely that this 
represents a failure of the nonsense suppression methodology.  We think it more likely 
that a receptor with Tyr-O3tBu incorporated at position α149 does not fold or does not 
assemble properly, and therefore no receptor appears on the surface.  Thus, the immediate 
vicinity of the agonist-binding site–the region very near αTrp 149–is quite sensitive, 
accepting a very close analog of its natural ligand, Tyr-OnQ (n=2-4), but nothing else. 
 
At α93 and γ55/δ57, Tyr-O3tBu is incorporated and gives measurable constitutive 
currents, but less than the cationic analog.  While direct contact between ACh and αTrp 
149 is well established, such is not the case for αTyr 93 nor γTrp 55/δTrp 57.  We 
propose that these ‘secondary’ sites are less intimately involved in defining the agonist-
binding site, but are better described as nearby.  Incorporating the tether at these sites 
disrupts the binding region, partly through a simple steric effect, since Tyr-O3tBu works.  
However, a tethered quaternary ammonium is more effective, suggesting these remote 
sites do sense some of the binding interactions associated with the quaternary ammonium 
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on ACh.   
 
It is important to appreciate that gating an ion channel is a complex process.  An 
agonist must bind to the receptor and initiate opening of the ion channel.  This is made 
even more complicated in the nAChR, where the ion channel and its gate are structurally 
remote from the agonist-binding site (24, 25).  In such a system, it is envisioned that 
binding of agonist induces a conformational change that shifts a pre-existing equilibrium 
between closed and open states of the channel toward the open state.  It is easy to imagine 
that the structural perturbation of introducing Try-OnQ or Tyr-O3tBu at one of the 
secondary sites could disrupt the structure of the protein in the vicinity of the agonist- 
binding site in the direction of the conformational change associated with opening.  Note 
that in all cases the tethered agonist is a weak agonist, indicating that the full effect on the 
open/closed equilibrium elicited by ACh is never achieved with a tethered agonist.  The 
tethered agonist essentially pushes the receptor along the path toward opening, or, stated 
differently, perturbs the gating equilibrium, but less effectively than the true agonist.  
Precisely at the agonist-binding site, αTrp 149, the structural requirements are more 
strict, and an optimal tether produces a large effect. 
 
Very recently, Sullivan and Cohen described tethered agonist studies in which 
potential tethered agonists were incorporated by reacting Cys residues introduced by site 
directed mutagenesis with various MTS reagents (17).  At α149 the Cys mutation made 
the receptor unresponsive to ACh, which is not surprising given the crucial role of αTrp 
149 in agonist binding (13).  At α93, Cys modification resulted in irreversible inhibition, 
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while at γ55 there was no effect for the Cys mutants after treatment with MTS reagents.  
Interestingly, though, reaction of the α198 Tyr/Cys mutant with methanethiosulphonate 
ethyltrimethlammonium (MTSET) produced a constitutively active receptor.  The effect 
was quite sensitive to the length and orientation of the tethered group, in that lengthening 
or shortening the tether by one methylene group negated the tethered agonist effect.  The 
successful tether introduced by MTS modification (CαCH2SSCH2CH2NMe3+) is much 
shorter than those investigated here, and so our failure to see constitutive activation with 
Tyr-OnQ at α198 is not surprising.  
 
An emerging model of the agonist-binding site of the nAChR 
 
Efforts to develop a detailed picture of the agonist-binding site of the nAChR 
continue in many labs.  Efforts to date are schematized in Figure 1.5.  The binding site 
involves several key residues located on several discontinuous ‘loops’ (26).  A large 
number of aromatic residues are associated with the agonist-binding site, along with 
perhaps one anionic residue.  One residue in particular, αTrp 149, has been shown to 
contact the agonist in the binding site (13).  
 
Another relevant observation is the high-resolution crystal structure of 
acetylcholine esterase (AChE) (27), the only natural ACh binding site for which such a 
structure was available before the solution of AChBP structure.  As was anticipated (1), a 
cation-π interaction is crucial for binding ACh.  In fact, the esterase uses a tryptophan, 
Trp 84, to bind the quaternary ammonium group of ACh.  In addition, the esterase 
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features a 20Å ‘aromatic gorge’ that leads from the surface of the enzyme to the active 
site and Trp 84.  The gorge is lined with over a dozen conserved aromatic residues that 
presumably guide the ACh to the active site using cation-π interactions and other effects.  
This structure was revealed at about the same time that many workers were identifying 
the large number of aromatic residues associated with the agonist-binding site of the 
nAChR.  The possibility that a comparable aromatic gorge would exist in the nAChR was 
immediately apparent.  Recently, Unwin has interpreted electron densities in the vicinity 
of the agonist-binding site as consistent with such a gorge, but the images are not yet of 
sufficient resolution to be decisive (24). 
 
If an aromatic gorge analogous to the one found in the AChE exists in the 
nAChR, then the results presented here put certain constraints on the model, as 
summarized in Figure 2.10.  Certainly, the bottom of the gorge and the final resting place 
of ACh are defined by αTrp 149, playing the role ascribed to Trp 84 in the esterase.  Note 
that of all the residues discussed as contributing to or being near the agonist-binding site 
(Figure 1.5), evidence for direct interaction with ACh exists only for αTrp 149.  The 
relatively strict structural requirement at αTrp 149 proposed here is consistent with the 
absence of ACh response seen for the Cys mutant at this site (17).  We propose that αTyr  
93 is near the bottom of the gorge, as evidenced by the fact that the shortest tether elicits 
a response at this site.  The OH of αTyr 93 is involved in a key hydrogen bond in the 
binding site, and we suggest this is a hydrogen bond to the protein backbone (12).  Given 
that tethered agonists at γ55/δ57 had a weaker ability to open the channel and that the two 
carbon tether is ineffectual, we position γ55/δ57 further up the gorge.  An ongoing debate 
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in the nAChR literature is whether the agonist-binding site is best thought of as being 
buried within the α subunits or whether it is at the subunit interfaces, α/γ and α/δ.  Our 
results clearly support a role for the γ/δ subunits.  However, the α/γ and α/δ subunit 
interfaces might be contributing to the gorge leading to the agonist-binding site, rather 
than actually structuring the binding site.  Finally, we include αTyr 198 as very near the 
agonist-binding site, based on the MTS studies of Cohen (17).  Of course, the model 
presented in Figure 2.10 is highly speculative at this point, and we look forward to further 
studies, both structural and mechanistic, to refine it. 
 
 
Figure 2.10.  The evolving view of the nAChR agonist-binding site.  Shown is a highly 
schematic view of an ‘aromatic gorge’ analogous to that proposed for ACh esterase.  
αTrp 149 lies at the bottom of the gorge and binds the quaternary ammonium group of 
ACh, playing the role of Trp 84 in the AChE.  αTyr 198 is near the bottom of the gorge, 
while αTyr 93 lies slightly up the gorge, and its OH forms an important hydrogen bond.  
γTrp 55/δTrp 57 lies further up the gorge. 
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More recently, the crystal structure of AChBP has been solved and revealed the 
binding site in great detail (see Chapter 3) (28).  From AChBP structure five aromatic 
residues form an open box (Figure 3.1A), which defines much of the agonist-binding site.  
Among the five aromatic residues, three of them were identified by the tethered agonist 
approach described here.  Another is the tyrosine identified by Cohen’s study.  In 
addition, an ammonium group (positively charged) from a molecule in the crystallization 
buffer was positioned directly over the analogous residue of αTrp 149, which is 
consistent with the cation-π interaction as expected.  Thus, the structure of AChBP has 
confirmed our results very nicely.  
 
In summary, we have shown that the tethered agonist approach via unnatural 
amino acid mutagenesis is a general tool for probing structure in the nAChR (18).  We 
fully expect it will be useful in other integral membrane proteins.  Using this approach we 
have now positioned three residues–αTrp 149, αTyr 93, and γTrp 55/δTrp 57 in loops B, 
A and D, respectively–very near the agonist-binding site and each with a distinct role.  
We anticipate that further application of this methodology will provide additional, useful 
insights.  Indeed, in the following chapter we will describe the identification of additional 
residues in loops C and E very near the agonist-binding site using a new tethered agonist.  
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Chapter 3 
 
 
Identification of Additional Residues Near the Agonist-Binding Site by a 
Tethered Agonist and Investigation of the Effect of an Intersubunit 
Hydrogen Bond on the nAChR Desensitization– 
Further Evidence that the N-terminal Extracellular Domain of 
nAChR Is Closely Related to AChBP      
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3.1 Introduction 
 
As mentioned earlier in Chapter 1, a small soluble protein from snail glial cells– 
ACh binding protein (AChBP)–has been discovered and characterized (1).  Its crystal 
structure has also been solved at 2.7 Å resolution (2).  The structure reveals the essential 
features of a key region–the agonist-binding site of the nAChR.  Moreover, the structure 
rationalizes almost every result from over 40 years of biochemical and 
electrophysiological studies of the agonist-binding site of the nAChR (3).   
 
There is a cavity at each interface between the subunits.  These cavities are lined 
by residues which were shown to be involved in ligand binding in nAChR by 
photoaffinity labeling and mutagenesis studies (4).  These cavities are located close to the 
outside of the pentameric ring.  The data do not validate (5) the suggestion that the 
“tunnel” seen in Torpedo nAChR electron microscopy pictures (6) is the access route to 
the ACh-binding site.  The ligand-binding residues are found on both the principal 
subunit (plus side) and the complementary subunit (minus side).  The residues on the 
principal subunit align with those on the α subunit of nAChR and are in loops between β 
stands.  The residues on the complementary subunit align with those on γ or δ subunits of 
nAChR and are mostly within β strands.  The principal side consists of residues coming 
from loop A (Tyr 89, i.e., αTyr 93), loop B (Trp 143 and His 145, i.e., αTrp 149 and 
αTyr 151), and loop C (Tyr 185, Cys 187, Cys 188, and Tyr 192, i.e., αTyr 190, αCys 
192, αCys 193, and αTyr 198). (The aligned residue in nAChR is preceded by the Greek 
letter indicating the subunit.)  The complementary side consists of residues coming from 
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loop D (Trp 53 and Gln 55, i.e., γTrp55/δTrp57 and γGlu57/δAsp59), loop E (Arg 104, 
Val 106, Leu 112, and Met 114, i.e., γLeu 109/δLeu 111, γTyr 111/δArg 113, γTyr 
117/δThr 119, and γLeu 119/δLeu 121), and loop F (Tyr 164, i.e., γAsp 177/δAla 183).   
  
 All residues in the binding site have been identified by photoaffinity labeling and 
mutagenesis studies.  All observed residues are conserved between ligand-binding 
subunits of nicotinic receptors except the loop F Tyr164 residue.  One negatively charged 
residue, Asp 161, that is very close to loop F is highly conserved.  The aligned residue in 
nAChR (γAsp 174/δAsp 180) has been shown to be important in ligand binding and 
about 9 Å away from α Cys 192/193 (7).  In the crystal structure of AChBP Asp 161 is 
one of the ligands of a Ca2+ ion near loop F.  So it is suggested that Tyr 164 might 
contribute to the ligand-binding area because of a Ca2+ site that orientates its lateral chain 
towards to loop C.  There is another residue identified by labeling studies, Trp 82 (αTrp 
86), which does not participate directly in ACh-binding.  Instead it is involved in 
hydrophobic core formation and located far (~15 Å) from the binding pocket.   
  
 Although the AChBP was crystallized in the absence of a specific binding site 
ligand, AChBP did contain a molecule of N-2-hydroxyethylpiperazine-N’-2-
ethanesulphonate (HEPES) from the buffer in the binding site cavity.  Each of the 
nitrogens of the piperazine ring is protonated, and an ammonium (positively charged) 
group was positioned directly over Trp143 (αTrp 149), making cation-π interactions as 
anticipated by our earlier studies (8).  When the earlier results for nAChR are mapped 
onto the new structure of AChBP, the remarkable image shown in Figure 3.1B emerges.  
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Loops A-D do indeed form a binding site, with loops E and especially F more remote. 
The disulfide bond is right in the middle of the action.  The binding site is shaped by the 
five key aromatic residues (Figure 3.1A), αTyr 93, αTrp 149, αTyr 190, αTyr 198 and 
γTrp 55/δTrp 57, which are aligned correspondingly with the AChBP residues Tyr 89, 
Trp 143, Tyr 185, Tyr 192 from the plus side and Trp 53 from the minus side.  
 
        
Figure 3.1.  The deduced structure of the agonist-binding site of the nAChR (adapted 
from ref. 3).  A. The open box, formed by five aromatic residues, that probably defines 
much of the agonist-binding site.  The view is derived from A by a 90° rotation clockwise 
around the vertical axis.  B. The key features of the nAChR agonist-binding site based on 
photoaffinity labeling and mutagenesis experiments are mapped onto Fig. 2b from ref. 2 
(page 271).  The agonist-binding site is denoted by π, emphasizing the importance of the 
aromatic residues in general and αTrp 149 in particular.  Also highlighted are the 
signature loops of both subunits, and the main immunogenic region (MIR).   
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 Undoubtedly, the crystal structure of AChBP has shed much light on our 
knowledge of the nicotinic receptors.  The structure also confirmed all our results 
discussed in Chapters 2 and 4.  The picture of the agonist-binding site of the nAChR is 
becoming more and more clear, especially for the binding of the quaternary ammonium 
group of ACh.  However, because of the absence of ligand in the structure of AChBP, 
precise positioning of ligands within the binding site remains to be elucidated.  For 
example, the relative orientation of the acetyl group of ACh is not known, although some 
suggestions have recently been made based on photoaffinity labeling studies (9).  In 
addition, with the crystal structure data in hand, the next major issue is to decipher the 
allosteric mechanism that mediates the activation and desensitization of the nAChR ion 
channel from a 20–30 Å distant agonist-binding site.  Finally, further evidence is desired 
to confirm the relevance of a small soluble protein from a snail to a receptor in the 
vertebrate central nervous system. 
  
 In order to gain more information on the position and orientation of ACh when it 
binds to the agonist-binding site, we docked the ACh molecule into the structure of 
AChBP.  Based on the model obtained from the docking study, we found that the acetyl 
group of ACh is orientated toward and very close to the side chain of Met 114 (γLeu 
119/δLeu 121) on the complementary subunit, which is pointing toward the binding 
pocket.  Based on this result, we designed and incorporated a new tethered agonist, lysyl-
carbamylcholine.  Upon incorporation into nAChR at several sites this tethered agonist 
produced constitutively active receptors, with significant activity seen at γLeu 119/δLeu 
121 as well as at αCys192 and αCys 193.  These results demonstrated that the loop E 
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residues γLeu 119/δLeu 121 on the complementary subunit are very close to the agonist-
binding site, and also suggested the orientation of the acetyl group of ACh in binding.  
After re-examination of the crystal structure around the binding pocket, we found an 
interesting hydrogen bond between the NH of the indole side chain of Trp 143 (αTrp 
149) and the carbonyl of a peptide bond of the complementary subunit.  The intersubunit 
location suggested that this hydrogen bond might play a role in the allosteric transitions 
of nicotinic receptors.  We therefore studied the effect of this hydrogen bond on the rate 
of desensitization.  We found that the receptors with mutants that abolish the hydrogen 
bonding ability slowed the desensitization of the receptor.  These results implied that this 
hydrogen bond might be one of the key elements that play a strategic role in the allosteric 
transitions of desensitization.  All the above results together not only provide more 
interesting information on the nAChR, but also provide additional evidence that the 
structure of AChBP is closely related to that of N-terminal extracellular domain of the 
nAChR.  
  
3.2 Docking Studies 
 
As mentioned earlier, AChBP is a structural and functional homologue of the 
amino-terminal ligand-binding domain of nAChR, thus it can be used as a model in 
structure based modeling.  The crystal structure of AChBP does not have any specific 
ligand bound in the binding site while on the other hand molecular docking is an 
important tool in studying ligand binding to receptors.  We thus can use molecular 
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docking to get a picture of the binding mode of ligands in the binding site.  Here we 
present our docking study of ACh to AChBP. 
 
 The crystal structure was minimized using the Dreiding force field (10) in the 
surface generalized Born (SGB) (11) continuum solvent after adding hydrogens and 
counter ions (see Chapter 5 for more details).  The overall rmsd change after 
minimization was 0.35 Å, which showed that the Dreiding force field is suitable to 
describe the protein.   
 
 Using the HierDock docking protocol (12), the binding conformation of ACh in 
AChBP is obtained (see Chapter 5 for more details).  Figure 3.2 shows ACh along with 
selected residues in the binding site of AChBP.  It is seen that the quaternary ammonium 
group is buried deep within the pocket formed by five aromatic groups (Y89, W143, 
Y185, Y192 and W53 from the complimentary subunit).  Interestingly, although the 
distances from the nitrogen atom of the quaternary ammonium to these five aromatic 
rings are similar (about 5 Å), the quaternary ammonium (positively charged) is only 
positioned directly over the face of the aromatic ring of Trp 143 (Figure 3.2A)–making 
the cation-π interaction as predicted by our earlier studies (8).  The faces of the other four 
aromatic rings are not positioned correctly to allow the negative electrostatic potential 
resulting from the quadrupole moment to interact with the cation favorably.  The 
implication of the docking results is that Trp 143 is unique because of orientation rather 
than close contact.  The interaction energies between the docked ACh and all these 
aromatic residues are calculated and listed in Table 3.1.  A test study of the binding 
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energy between ammonium ion and benzene has showed similar results from calculations 
using Dreiding force field (14.6 kcal/mol) and using ab initio quantum mechanics (15.38 
kcal/mol), which shows the cation-π interaction can be reproduced with the Dreiding 
force field.  As shown in Table 3.1, Trp 143 has the largest coulomb energy among the 
five aromatic residues, which is also consistent with the cation-π interaction.  Tyr 192 has 
the largest total interaction energy, partly because of a weak hydrogen bond (-1.167 
kcal/mol) that seems to form between its OH group and the carbonyl group of the ACh.  
The distance between the heavy atoms is 3.4 Å (141.5°).  Because this part of the binding 
site is readily accessible to solvent, it is also possible that this hydrogen bond is bridged 
by a water molecule.  Invoking a bridging water that links the OH of αTyr 198 to the 
acetyl of ACh would explain the previously reported observation that O-Me-Tyr (4-MeO-
Phe) at this position gives an EC50  that is less than two fold different than wild-type (13).  
This residue cannot hydrogen bond directly to the agonist, but a water molecule could 
still bridge from the methoxy group to the agonist, now acting as a hydrogen bond donor 
at both ends of the bridge.  
 
Residue Total non-bond 
interaction energy  
Van der Waals 
energy 
Coulomb 
energy 
H-bond 
Y192 -5.575 -2.652 -1.756 -1.167 
W143 -3.288 -0.571 -2.717 0.000 
Y89 -2.837 -1.116 -1.721 0.000 
W53 -2.211 -2.281 -0.070 0.000 
Y185 -1.183 -2.230 1.047 0.000 
Table 3.1.  Interaction energies (kcal/mol) between ACh and the five aromatic residues in 
the binding site. 
 60
A. 
.  
B. 
 
Figure 3.2.  Two different views of docked ACh in the binding site of AChBP.  Selected 
residues contributing to the agonist binding are shown.  A. The quaternary ammonium of 
ACh is positioned directly over the face of the aromatic ring of Trp 143.  B. The acetyl of 
ACh is oriented toward the disulfide bond and the side chain of Met 114. 
3.4 Å
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 Another interesting result of the docking study is the identification of the 
orientation of the acetyl group of ACh.  As shown in Figure 3.2, the acetyl group of ACh 
is oriented toward the disulfide bond formed by Cys 187 and Cys 188 as well as the side 
chain of a residue from the complimentary subunit, Met 114.  The disulfide bond between 
adjacent half cysteinyl residues is present in all nicotinic receptors and reduction of the 
disulfide bond in the nAChR affects both ligand binding and channel gating (14).  On the 
other hand, the aligned residue of Met 114 in the nAChR family is not highly conserved 
and is often a large hydrophobic residue in non-α subunits.  In addition, based on the 
docking studies Met 114 seems to have the right orientation and distance for introducing 
a tethered agonist, such that a properly designed tethered agonist might be able to map 
out the orientation of the acetyl group of ACh.  Therefore, the aligned residue of Met 114 
in nAChR seems to be a perfect candidate position to introduce a new tethered agonist.  
 
3.3 Incorporation of Lysyl-carbamylcholine at γLeu 119/δLeu 121 Resulted in 
Significant Constitutive Activity of the Receptor 
 
With the results of the docking study, we were interested in exploring the 
orientation of the acetyl group of ACh when it binds to the agonist-binding site.  We want 
to introduce the acetyl part into the tethered agonist in addition to the quaternary 
ammonium group, which the series of tethered agonists described in Chapter 2 contain.  
However, the molecule of ACh is not a good choice because it is very easily hydrolyzed.  
Compared with ACh, another nicotinic agonist, carbamylcholine (CCh) (Figure 3.3) is 
much more stable (the first order rate constant for hydrolysis of CCh is about one order of 
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magnitude smaller than that of ACh (15).).  The equilibrium binding constants for CCh 
are similar to those for ACh, while doubly liganded CCh opens receptors at a slower rate 
than doubly liganded ACh.  But compared with tetramethylammonium (TMA), CCh is a 
better agonist in terms of both agonist binding and channel opening (Table 3.2) (16).  By 
incorporation of a carbamyl group to mimic the ester moiety of the agonist, which was 
suggested to speed both binding and channel opening (16), we might be able to not only 
map the orientation of the acetyl group of ACh in binding, but also increase the 
effectiveness of the tethered agonist.  Base on the above reasons, the unnatural amino 
acid lysyl-carbamylcholine (Figure 3) that has been made is a perfect candidate as a new 
tethered agonist.  
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acetylcholine carbamylcholine
lysyl-carbamylcholine  
Figure 3.3.  The structure of acetylcholine, carbamylcholine and lysyl-carbamylcholine. 
 
Ligands Channel opening 
rate constants (s-1) 
Equilibrium binding 
constants (µm) 
ACh 60000 20 and >650 
CCh 11500 14 and 570 
TMA 3000 525 and 12800 
 
Table 3.2.  The channel opening rate constants and the equilibrium binding constants of  
the nicotinic ligands for the embryonic mouse muscle nAChR.  (Data taken from ref. 16.) 
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Based on the docking structure and the earlier discussion, γLeu 119/δLeu 121 (the 
equivalent of Met 114 in AChBP) is a great position to introduce the lysyl-
carbamylcholine residue.  Therefore we made the mutations that contain amber codon 
(TAG) at γLeu 119 and δLeu 121.  After we incorporated the lysyl-carbamylcholine into 
nAChR at γLeu 119/δLeu 121, we observed constitutive currents as large as 2 µA, which 
can be blocked by the nicotinic channel blocker TMB-8.  Figure 3.4A shows the 
constitutive current that can be blocked by TMB-8, which varied on different experiment 
dates depending on the expression levels.  The expression level of the mutant receptor 
with lysyl-carbamylcholine at γLeu 119/δLeu 121 is relatively high based on ACh-
induced currents (Figure 3.4B), although it varied to some extent on different experiment 
dates.  The wild-type receptor gave ACh-induced current in the same range as the mutant 
receptor, but no constitutive current.  We should mention that the constitutive activity for 
the mutant receptor was only observed with the Leu to Ser mutation at the 9’ position of 
M2 region of the β subunit (see discussion in Chapter 2). 
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Figure 3.4.  The electrophysiological results of incorporation of lysyl-carbamylcholine 
into nAChR at γLeu 119/δLeu 121 on three different experiment dates.  A. The 
constitutive current that can be blocked by 10 µM TMB-8.  B. The ACh (25 µM)-induced 
current. 
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As discussed in Chapter 2, we use the ratio of the constitutive current that is 
blocked by TMB-8 to the ACh-induced current as a gauge of the effectiveness of a 
tethered agonist in activating the receptor.  The concentrations of TMB-8 and ACh are 
always 10 µM and 25 µM, respectively, for measuring the currents that are used to 
calculate the ratios unless otherwise indicated.  The ratio of TMB-8-blocked current to 
ACh-induced current for lysyl-carbamylcholine at γLeu 119/δLeu 121 is between 0.3-0.9, 
varying to some extent in different experiments (Figure 3.5). Therefore its effectiveness 
is between what we have observed for Tyr-OnQ at αTyr 93 and γTrp 55/δTrp 57.   
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Figure 3.5.  The relative effectiveness of lysyl-carbamylcholine at γLeu 119/δLeu 121 on 
three different experiment dates. 
  
We also incorporated Tyr-O3Q at γLeu 119/δLeu 121 to compare with lysyl-
carbamylcholine.  It turned out that the effectiveness for the two tethered agonists was 
similar at this position (Figure 3.6).  Note that the tether lengths (the distance between the 
quaternary ammonium group and the Cα) in lysyl-carbamylcholine and Tyr-O3Q are 
very similar.  One of the differences between the two tethers is the presence of the 
carbamyl bond in lysyl-carbamylcholine, which might be the cause of the slightly higher 
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activity seen for lysyl-carbamylcholine at this position.  The other difference is that the 
side chain of lysyl-carbamylcholine is relatively more flexible than that of Tyr-O3Q. 
 
Figure 3.6.  Comparison of the effectiveness of the two tethered agonists at γLeu 
119/δLeu 121. 
 
 Since Tyr-O3Q produced constitutively active receptors at γLeu 119/δLeu 121, 
we decided to try the Tyr-OnQ series to see the effect of varying chain length at this 
position on the activity of the tethered agonist.  We found that the effectiveness of the 
tether with 3 or 4 methylene groups were more than 10-fold higher than that of the 
shortest or the longest tether (Figure 3.7B).  These results suggest that at position γLeu 
119/δLeu 121, both of the medium length tethers can be accommodated very well in the 
agonist-binding site and activate the receptor, while the other two tethers are either too 
short or too long to be positioned properly.  We also tried the neutral compound Tyr-
O3tBu.  No constitutive current was observed, although the ACh-induced current is high 
(Figure 3.7A).  This result implied that steric effects might not be involved here. 
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Figure 3.7. The results of incorporation of Tyr-OnQ (n=2-5) and Tyr-O3tBu at γLeu 
119/δLeu 121.  A. The ACh (25 µM)-induced current.  B. The relative effectiveness of 
Tyr-OnQ. 
  
In addition to γLeu 119/δLeu 121, we also tried lysyl-carbamylcholine at several 
other positions around the agonist-binding site.  As for the three positions that we have 
seen constitutive activity earlier, we found that incorporation of lysyl-carbamylcholine at 
αTyr 93 and γTrp 55/δTrp 57 also resulted in constitutively active receptors but not at 
αTrp 149.  The ratios of TMB-8-blocked current to ACh-induced current are 0.25 and 
0.18 for the mutant receptors with lysyl-carbamylcholine at αTyr 93 and γTrp 55/δTrp 
57, respectively.  Therefore at these two positions lysyl-carbamylcholine exhibited some 
but lower effectiveness than Tyr-O3Q (refer to Figure 2.5).  The constitutive activity for 
both tethers at these two positions is not hard to understand, considering the similar 
distance between the Cα and the quaternary ammonium for these two tethered agonists 
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and the tolerance for the tether length at these two positions (17).  The somewhat lower 
activity can also be explained by the differences between the two tethers discussed 
earlier.  At αTrp 149 the expression level with lysyl-carbamylcholine was relatively low 
based on the ACh-induced current.  Still, no constitutive current was observed.  We 
therefore consider this as a negative result, which is consistent with the previous 
conclusion that there is a stricter geometric requirement for receptor activation around the 
region very near αTrp 149 (17).   
 
 Besides the positions discussed above, we also observed constitutive activity for 
nAChR at αCys 192 and αCys 193 upon incorporation of lysyl-carbamylcholine.  The 
expression levels are relatively low at these two positions, especially for mutant receptor 
with lysyl-carbamylcholine at αCys 192.  This is very likely due to the breakage of the 
disulfide bond between these two cysteines, since the reduction of the disulfide has been 
shown to affect both ligand binding and channel gating (14).  At αCys 193 the 
constitutive currents that could be blocked by TMB-8 were about 150 nA while the ACh-
induced currents were about 300 nA, giving a ratio of about 0.5 (Figure 3.6).  Therefore 
the effectiveness of the tether lysyl-carbamylcholine at αCys 193 is similar to that at 
γLeu 119/δLeu 121.  At αCys 192, although the TMB-8 blocked currents were in the 
same range as that at αCys 193, the ACh-induced currents were so small that they were 
only about 100 nA even at 500 µM of ACh.  Thus the ratio of the TMB-8-blocked current 
to ACh-induced current is large.  It is about 2.5 for 500 µM ACh and should be even 
larger for 25 µM of ACh (Figure 3.8).  This result implied that lysyl-carbamylcholine 
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was a much stronger tethered agonist at αCys 192 than at αCys 193 and γLeu 119/δLeu 
121.   
 
Figure 3.8.  The relative effectiveness of tethered agonist lysyl-carbamylcholine at αCys 
192 and αCys 193. 
 
 Based on all of the above results, lysyl-carbamylcholine is an effective tethered 
agonist at αTyr 93, αCys 192, αCys 193, γTrp 55/δTrp 57, and γLeu 119/δLeu 121.  All 
these residues have been identified by photoaffinity labeling studies except γLeu 
119/δLeu 121.  Although γLeu 119/δLeu 121 has been included as one of the loop E 
residues that contribute to the agonist binding pockets (5), there has been very little 
evidence that demonstrates its direct involvement in agonist binding.  Neither 
photoaffinity labeling nor mutagenesis studies have identified this residue as being 
crucial for agonist binding.  It has only been identified as one of the residues that 
contribute to α-bungarotoxin binding based on the decreased binding upon modification 
of the Leu to Cys mutant by MTSET (18).  Here we showed that at γLeu 119/δLeu 121 a 
tethered agonist lysyl-carbamylcholine could be positioned properly in the agonist 
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binding pocket and thus activate the receptor.  These results confirmed that that γLeu 
119/δLeu 121 was very close to the agonist-binding site, which is consistent with the 
crystal structure of AChBP and the results of the docking study. 
 
 Among all of the positions above where incorporation of lysyl-carbamylcholine 
resulted in constitutively active receptors, the tether lysyl-carbamylcholine is more 
effective at αCys 192, αCys 193, and γLeu 119/δLeu 121 than at αTyr 93 and γTrp 
55/δTrp 57.  This result suggested that the tether lysyl-carbamylcholine could be 
positioned better at αCys 192, αCys 193, and γLeu 119/δLeu 121 than at αTyr 93 and 
γTrp 55/δTrp 57.  This is consistent with the docking model, in which the acetyl group of 
ACh is oriented in the way that it makes close contact with residues Cys 187, Cys 188 
and Met 114 (αCys 192, αCys 193, and γLeu 119/δLeu 121), while the quaternary 
ammonium group of ACh is located in a box formed by the five aromatic residues 
(Figure 3.2).  A recent photoaffinity labeling study has identified αTyr 190, αCys 192, 
αCys 193, and αTyr 198 as the residues that might contribute to the binding of the ester 
moity of ACh (9).  But the labeling molecule used (DCTA, (diazocyclohexadienoyl-
propyl)-trimethylcmmonium) is less closely related to ACh than lysyl-carbamylcholine in 
terms of structure.  In our study we obtained negative results at αTyr 190 and αTyr 198.  
Our results suggested among the loop C residues, αCys 192 and αCys 193 could position 
the carbamylcholine moiety of the tether chain more properly than αTyr 190 and αTyr 
198 and therefore activate the receptor.  Combined with the docking study, our results 
implied that the acetyl group of ACh was very likely oriented towards the side chain of 
αCys 192, αCys 193, and γLeu 119/δLeu 121. 
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 The above results also provide further evidence that supports the close relevance 
of AChBP to nAChR.  In addition, the success of a new tethered agonist at a new position 
has showed that the tethered agonist approach indeed can be a general and very useful 
tool in mapping the structure of ion channel proteins. 
 
3.4  Investigation of the Effect of an Intersubunit Hydrogen Bond on Desensitization 
 
 Careful examination of the crystal structure of AChBP revealed an intersubunit 
hydrogen bond between the NH of the indole side chain of Trp 143 (αTrp 149) and the 
peptide carbonyl of Met 114 (γLeu 119/δLeu 121) on the complementary subunit.  As 
discussed earlier in Chapter 1, the subunit interface might play a crucial role in the 
allosteric mechanism that mediates the activation and desensitization of the nAChR.  It 
has been inferred (5) that AChBP was crystallized in a frozen “desensitized” (D) state, 
based on the high affinity of AChBP for nicotinic ligands and Hill coefficients that are 
either equal to or below unity (1).  This led to the hypothesis that the basal (B) activatable 
conformation of nAChR derives from the AChBP structure by a reorganization of the 
quaternary structure.  Therefore, this hydrogen bond at the interface of two subunits 
might play a key role in allosteric transitions of desensitization of the nAChR by 
stabilizing the more compact conformation of the D state.  
 
 We therefore decided to explore this interesting hydrogen bond further.  Based on 
the above hypothesis, we think that incorporation of tryptophan analogs that abolish the 
hydrogen bonding abilities of the indole side chain at αTrp 149 may destabilize the 
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desensitized state of the nAChR.  Here the nonsense suppression methodology provides 
us an indispensable tool that allows us to introduce unnatural amino acids with very 
subtle changes compared with their natural analog into the receptors.  This would not 
have been possible with traditional site-directed mutagenesis.  We have incorporated 
several tryptophan analogs, including N-methyl tryptophan (N-Me-Trp), 1-
naphthylalanine (1-Np-Ala) and 2-naphthylalanine (2-Np-Ala) (Figure 3.9).   
 
       
N
H
CH2
CH2
N
CH2
CH3
CH2
Trp N-Me-Trp 1-Np-Ala 2-Np-Ala  
 Figure 3.9.  Structures of tryptophan and its analogs.  
 
We incorporated tryptophan and its analogs into nAChR at Trp 149 and measured 
the current response to ACh using two-electrode voltage clamp.  The receptor was 
desensitized by prolonged exposure to ACh.  Figure 3.10 shows representative traces in 
this set of experiments.  The desensitization phase was fit using a two exponential fit in 
Clampfit, and the weighted rate constants were calculated.  As shown in figure 3.11 in 
most cases the desensitization rate constants for wild-type receptor are about 2.5-6 fold 
larger than those of the mutant receptors lacking the hydrogen bonding abilities.  Thus, 
the receptor desensitizes more slowly in the absence of the hydrogen bond between the 
indole side chain of Trp 149 and the carbonyl backbone on the neighboring subunit.  
These results suggested that this intersubunit hydrogen bond is very likely one of the key 
elements in stabilizing the desensitized state of the receptor.  Considering the strategic 
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location of this hydrogen bond–not only intersubunit but also within the binding pocket– 
it seems reasonable to propose that it is involved in transducing the binding event into a 
conformational change, and therefore plays a pivotal role in the allosteric mechanism of 
the receptor desensitization.   
 
A.            B. 
 
 
 
 
C.            D. 
        
 
 
 
 
Figure 3.10.  Representative traces in the desensitization experiments.  (A) Wild type 
(Trp), (B) 1-Np-Ala, (C) N-Me-Trp, (D) 2-Np-Ala.  The green cursors indicate the start 
and the end of the application of ACh.  The concentrations of ACh used are 200 µM for 
wild type and mutant with 1-Np-Ala, and 400 µM for mutant with N-Me-Trp and 2-Np-
Ala.  The traces are in black and the fitting curves are in blue.  For wild-type receptor (A) 
two applications of ACh were performed, only the first one was fit. 
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Figure 3.11.  The weighted rate constants for desensitization of wild-type and mutant 
nAChRs. The concentrations of ACh used are indicated.  (Weighted rate constants are 
calculated as following: r*=1/[τ1xA1/(A1+A2)+τ2xA2/(A1+A2), where τ1 and τ2 are the 
time constants for the slow and fast phase respectively in the two exponential fit, A1 and 
A2 are the amplitudes, respectively.)  
 
 The expression levels of the mutant receptors with different tryptophan analogs 
varied.  The mutant with 1-Np-Ala expressed very well, giving large ACh-induced 
currents (2000-3000 nA at 200 µM of ACh) in the same range as wild-type receptor 
(Figure 3.12).  However, the mutants with N-Me-Trp and 2-Np-Ala expressed relatively 
poorly, with only 200-300 nA ACh-induced current at 400 µM of ACh.  Occasionally 
even no ACh current was seen, such as for the mutant receptor with 2-Np-Ala in the 
experiment conducted on December 20 (Figure 3.12).   
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Figure 3.12.  ACh-induced current for wild-type and mutant nAChRs with tryptophan 
analogs at αTrp 149.  The concentrations of ACh (µM) used are indicated. 
 
 The mutant nAChRs with these tryptophan analogs at αTrp 149 have actually 
been studied before in searching for the cation-π interaction, and the EC50 values for 
these mutant receptors have been measured (8).  During our experiments we observed 
deviations of the EC50 values from the previous data.  Thus we repeated the 
measurements.  Figure 3.13 shows the representative dose response curves for these 
mutant nAChRs with unnatural tryptophan analogs at αTrp 149.  As shown in Table 3.3, 
the EC50 value for 1-Np-Ala mutant is about 5-fold lower than that of wild-type receptor, 
while the EC50 value for 2-Np-Ala mutant is 5-fold higher, and the EC50 for N-Me-Trp is 
in between.  Compared with wild-type EC50 the trends of the EC50 changes for the three 
mutants are different although they all lack the hydrogen bonding ability.  Therefore the 
differences in EC50 values between the mutants and wild type are due to some other 
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structural aspects; further experiments will be needed to distinguish among the possible 
reasons.  It is worth mentioning that the mutant with 1-Np-Ala at αTrp 149 is the first 
mutant that has been found to be substantially more active than wild-type nAChR. 
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Figure 3.13.  Representative dose-response measurements for wild-type and mutant 
nAChRs with tryptophan analogs at αTrp 149.   
 
Side Chain EC50 Hill coefficient 
Trp 56.2±0.77 1.5±0.02 
1-Np-Ala 9.6±0.80 1.1±0.07 
N-Me-Trp 84.6±1.5 1.5±0.04 
2-Np-Ala 260.7±12.1 1.2±0.09 
  
Table 3.3.  The EC50 values and Hill coefficients for wild-type and mutant nAChRs with 
tryptophan analogs at αTrp 149.   
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3.5  Conclusions and Future Directions 
 
The high-resolution structure of AChBP has certainly advanced our understanding 
of the nAChR.  Here we present a docking study of ACh to AChBP in conjunction with 
several experiments that were designed based on the docking model and in return 
confirmed the docking structure.  Incorporation of a new tethered agonist, lysyl-
carbamylcholine, which contains a carbamyl group to mimic the acetyl group of ACh in 
addition to the quaternary ammonium group, resulted in constitutively active receptors 
with significant effectiveness at αCys 192, αCys 193, and γLeu 119/δLeu 121.  We 
therefore concluded that all these three residues, including the loop E residues γLeu 
119/δLeu 121 on the complementary subunits, are very near the agonist-binding site. In 
addition, we investigated the role of an intersubunit hydrogen bond between the NH of 
the indole side chain of Trp 143 and the carbonyl of the peptide backbone on the 
complementary subunit.  The mutant receptor with tryptophan analogs that lack the 
hydrogen bonding abilities desensitized more slowly than wild-type receptor.  These 
results suggested that this intersubunit hydrogen bond is very likely one of the key 
elements in stabilizing the desensitized state of the receptor, and therefore play a strategic 
role in the allosteric mechanism of the receptor desensitization.   
 
All the results discussed above revealed new interesting information on both 
agonist binding and allosteric control of the nAChR.  In addition, it provided further 
evidence that the soluble protein AChBP from snail glial cells is closely related to and 
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can be used to deduce the N-terminal extracellular domain of the vertebrate 
neurotransmitter receptor nAChR. 
 
There are several other experiments that can be done to further explore different 
aspects of the project.  First of all, the carbamylcholine derivatives of ornithine and 
homolysine, which are one carbon shorter and one carbon longer, respectively, than 
lysyl-carbamylcholine, can be prepared and incorporated into nAChR to investigate the 
effect of varying tether chain length on the effectiveness of the tether, therefore mapping 
out the geometric requirements in agonist binding.  Based on the result with Tyr-OnQ at 
γ119/δ121, we may predict that the one carbon longer tether may work as well as lysyl-
carbamylcholine while the shorter one may not.  Also, the nAChR is known for its 
pharmacological diversity.  It would be very interesting to see how nicotine binds to the 
agonist-binding site using molecular docking since nicotine has been thought to bind the 
receptor differently compared with ACh.  Finally, it has been shown that substitution of 
amino acid with an α-hydroxy acid to make the amide-to-ester mutation makes the 
carbonyl a poorer hydrogen bond acceptor (19).  We can therefore study the interesting 
hydrogen bond further by replacing the residue C-terminal to γLeu 119/δLeu 121, whose 
peptide bond carbonyl is the hydrogen bond acceptor, with an α-hydroxy acid.  This 
should weaken the hydrogen bond and therefore affect the receptor desensitization.   
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Chapter 4 
 
 
 
Efforts Toward Preparing a Short Tethered Agonist and 
Its Introduction into nAChR by Chemical Modification 
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4.1  Introduction 
 
As mentioned in Chapter 2, Sullivan and Cohen observed constitutively active 
receptors upon modification of cysteine at αTyr 198 by MTSET (1).  They introduced 
cysteine mutants by traditional mutagenesis and used sulfhydryl-reactive reagents to 
tether primary or quaternary amines at several positions around the agonist-binding site 
of the nAChR.  In most cases, the tethered amines acted as irreversible antagonists.  But 
at αTyr 198, MTSET modification of cysteine resulted in activation of the receptor.  The 
effect was very sensitive to the length and orientation of the tethered group, in that 
lengthening or shortening the tether by one methylene group negated the activation 
effect.  The inward current resulting from the MTSET treatment of cysteine at α198 was 
as large as a few microamps.  This effect was seen even without the additional Leu9’Ser 
mutation required in our studies (see Chapter 2), which could indicate quite efficient 
activation.  This tethered agonist is much shorter than those discussed earlier in Chapters 
2 and 3.  It would be interesting to see whether we could observe constitutive activation 
in the absence of the Leu9’Ser mutation by incorporating this tether at αTyr 198 by 
nonsense suppression.  We therefore decided to make this shorter and more flexible 
tethered agonist–MTSET modified cysteine, i.e., S-[(2-trimethylammonium)-ethyl]-
cysteine (Figure 4.1).   
 
   HN CO
S
S
N
 
 
Figure 4.1.  The structure of MTSET-modified cysteine.   
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4.2  Efforts toward Preparing a Short Tethered Agonist–MTSET-Modified Cysteine  
 
For use in the unnatural amino acid methodology, the synthetic target is the amino 
acid with the side chain in place, the amino group protected, and the carboxylate 
activated as a cyanomethyl ester (2, 3).  The purpose of activation of the carboxylate 
group is to facilitate the coupling of the amino acid with the dinuleotide dCA (5’-
phospho-2’-deoxyribocytidylriboadenosine) to form the dCA-amino acid complex, which 
is then ligated to tRNA (see chapter 5 for details).  The amino group of the amino acid is 
protected by a nitroveratryloxycarbonyl (NVOC) group that will be removed by 
photolysis right before injecting the tRNA-amino acid into a Xenopus oocyte.  The step to 
put on the NVOC group is straightforward and usually done at the beginning of the 
synthesis, while the formation of the cyanomethyl ester is usually carried out in the final 
step and is challenging in certain cases.    
 
 The planned synthetic route to MTSET-modified cysteine is outlined in Scheme 
4.1.  It does not seem to be problematic.  Indeed, everything worked fine until the last 
step.  MTSET has been widely used in biological studies, but it has not been reported to 
be used in organic synthesis.  There are only a few instances of literature (4-6) for the 
preparation of disulfides with thio and methanethiosulfonates containing a primary or a 
secondary amine.  I tried several conditions for the reaction with MTSET: CsCO3/DMF, 
CsF/CH3CN and C2H5OH/CH2Cl2 with or without C2H5ONa.  It turned out the reaction 
went best in C2H5OH/CH2Cl2 with C2H5ONa.  Athough the reaction did go based on 
HPLC and the mass spectra showed the right peak, 1H NMR indicated that the product 
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was not pure, but rather a mixture.  One major component of the mixture was the free 
acid – N-NVOC-S-[(2-trimethylammonium)-ethylthio]-cysteine.  This suggested that the 
cyanomehtyl ester was easily hydrolyzed.  In addition, there were some other 
complications of the reaction.  One of them was the disproportionation of the disulfide 
(Scheme 4.2).  We observed the disproportion product based on mass spectra and 1H 
NMR after separating one peak in HPLC.  We attempted the coupling reaction with 
dinucleotide dCA using the crude product and failed.  The major peak in HPLC after the 
couplilng reaction was N-NVOC-S-[(2-trimethylammonium)-ethylthio]-cysteine, again 
the hydrolyzed product of the cyanomethyl ester.   
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Scheme 4.1.  The synthetic route for N-NVOC-S-[(2-trimethylammonium)-ethylthio]-
cysteine cyanomethyl ester. 
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Scheme 4.2. The disproportionation of the disulfide of N-NVOC-S-[(2-
trimethylammonium)-ethylthio]-cysteine cyanomethyl ester. 
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 Since we had made N-NVOC-S-trityl-cysteine cyanomethyl ester, we also tried 
its coupling with dCA followed by the deprotection of the trityl group and the reaction of 
MTSET with dCA-cysteine (Scheme 4.3).  However, the disadvantage of this procedure 
is that mass spectroscopy is the only informative way for characterization of the product.  
In addition, the phosphoester bond in dCA was vulnerable to the TFA used for the 
deprotection of the trityl group, which led to a low yield.  We did not observe the final 
product, which was very likely because of the instability of the ester bond between the 
amino acid and the dinucleotide. 
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Scheme 4.3. Synthesis of dCA- N-NVOC-S-[(2-trimethylammonium)-ethylthio]-cysteine 
beginning with the coupling of N-NVOC-S-trityl-cysteine cyanomethyl ester with dCA 
followed by the deprotection of trityl group and the reaction of MTSET.  
 
We think the instability of the cyanomethyl ester is due to the electronic effect of 
the quaternary ammonium group on the carbonyl of the ester bond (Figure 4.2) even 
though the 9-membered ring is not greatly favored.  Such a mechanism has been 
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proposed to explain the instability of ACh (7, 8).  In addition, the compound containing a 
quaternary ammonium group tends to be very hygroscopic. Actually, we had encountered 
difficulties in our earlier efforts to make amino acids containing quaternary ammonium 
groups with a short side chain, such as those shown in Figure 4.3 (9).  When we prepared 
the Tyr- OnQ series and lysyl-carbamylcholine, we found that we had to form the 
cyanomethyl ester first and then add the quaternary ammonium group at the final stage 
using a two step amination sequence (see Chapter 5 and ref. 5 for more details).  The 
advantage of this strategy is that the final product, the amino acid containing the 
quaternary ammonium group, just precipitated from the reaction solution and could be 
used in the following coupling reaction with dCA without further purification by HPLC.  
For the synthesis of the MTSET-modified cysteine here, we could use a similar 
procedure.  However, it is still possible that it wouldn’t work here, since the success in 
the preparation of Tyr-OnQ and lysyl-carbamylcholine could be because they are not as 
labile as MTSET-modified cysteine, due to the longer chain length and the rigidity of the 
chain, especially in the case of Tyr-OnQ.  After we tried a few alternative ways to couple 
the amino acid with dCA without forming the cyanomethyl ester and failed (see below), 
we decided to test the potential application of this unnatural amino acid by some 
biological experiment (see section 4.3) before we make further efforts in its synthesis.  
O
S
S
N
O
NVOC-HN
H2O R  
Figure 4.2.  A schematic of the electronic effect of the quaternary ammonium on the 
instability of the ester bond. 
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Figure 4.3.  Amino acids containing a short chain with a quaternary ammonium group at 
the end. 
 
After the failures to make the cyanomethyl ester, we decided to try some 
alternative methods to couple the amino acid with dinucleotide dCA just using N-NVOC-
S-[(2-trimethylammonium)-ethylthio]-cysteine since it is straightforward to prepare it 
(Scheme 4.4).   
1) NVOC-Cl
S S
O
O
N
H2N
S
Trityl
O
OH
NVOC-HN
SH
O
OH
NVOC-HN
S
O
OH
S
N
2) TFA/Et3SiH/CH2Cl2 EtOH/CH2Cl2
 
Scheme 4.4.  Synthesis of N-NVOC-S-[(2-trimethylammonium)-ethylthio]-cysteine.  
 
 Chamberlin and coworkers reported the method of coupling N-protected amino 
acids with dinucleotide dCA using carbonyldiimidazole (CDI) to activate the carboxylate 
group in aqueous solution (Scheme 4.5) (10, 11).  The reason they use water as solvent is 
to avoid a possible side-reaction, the acylation of the 4-amino group of cytidine (12).  It 
was reported as a one-pot procedure without isolating the amino acid imidazolide, but the 
yield was very low, only 6% (10).  I tried this reaction using both N-NVOC-S-[(2-
trimethylammonium)-ethylthio]-cysteine and a model amino acid, αN-NVOC-εN-Boc-L-
Lysine.  The reaction worked for the model amino acid, although the yield was extremely 
low (1%).  However, we didn’t observe the coupling product for N-NVOC-S-[(2-
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trimethylammonium)-ethylthio]-cysteine.  We think the imidazolide formed after the 
activation of N-NVOC-S-[(2-trimethylammonium)-ethylthio]-cysteine with CDI was 
hydrolyzed back to the acid.   
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Scheme 4.5.  The method of coupling the N-protected amino acid with dinucleotide dCA 
using CDI in aqueous solution. 
 
 When Schultz and coworkers first reported the in vitro nonsense suppression 
method for unnatural amino acid incorporation, the method for dCA-AA coupling they 
used involved the protection of the 4-amino group of the cytidine in dCA with a 
nitrophenylthio (NPS) group and then coupling of the N-protected amino acid with NPS-
dCA using CDI followed by the deprotection of the NPS group with thiosulfate (Scheme 
4.6) (13, 14).  Although the coupling reaction was run in dry DMSO, the deprotection 
step was carried out in an aqueous solution of thiosulfate.  We obtained the same results 
as the other procedure: the reaction worked for the model amino acid αN-NVOC-εN-Boc-
L-Lysine, but not for N-NVOC-S-[(2-trimethylammonium)-ethylthio]-cysteine.  We 
think that this procedure suffers from the complications associated with the protection 
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and deprotection of dCA, but the failure is mainly due to the instability of ester bond 
between the amino acid and the ribose of the dinucleotide. 
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Scheme 4.6.  The method of coupling the N-protected amino acid with NPS-protected 
dinucleotide dCA using CDI in anhydrous DMSO. 
 
 After we encountered these hurdles in obtaining the MTSET-modified cysteine 
and its complex with dinucleotide dCA, we decided to test the potential application of 
this short tethered agonist with biological experiments before we put further efforts into 
the synthesis.   
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4.3  MTSET-Modification of Cysteine Incorporated by Nonsense Suppression 
Resulted in Constitutively Active Receptors 
  
 One major purpose of attempting to incorporate this short tethered agonist into 
nAChR was to obtain strong constitutive activity, which therefore could be observed 
without using the Leu9’Ser mutation in M2 of the β subunit.  This was based on the 
significant effect of activation seen in Cohen and coworkers’ results (1).  However, we 
should mention that the cysteine mutation was introduced by traditional site-directed 
mutagenesis in their work.  One of the limitations of the unnatural amino acid 
mutagenesis methodology is the relatively low suppression efficiency compared with 
traditional site-directed mutagenesis.  Actually, the amount of surface receptors 
determined by 125I-α-bungarotoxin binding was about 4 fmol for wild-type receptors and 
2 fmol for the cysteine mutants.  This is more than 10 times the amount we can obtain by 
nonsense suppression.  This means that we probably wouldn’t be able to observe strong 
activation after we incorporate the MTSET-modified cysteine into nAChR by nonsense 
suppression if the expression level is not high enough.  Assuming the expression levels 
for mutant receptors with cysteine or MTSET-modified cysteine incorporated by 
nonsense suppression methodology are similar, the signal from chemical modification of 
cysteine by MTSET should be similar to that from incorporation of MTSET-modified 
cysteine.  We therefore incorporated a cysteine residue by nonsense suppression at α198 
to test how much activation we could obtain by MTSET modification, both in the 
presence and in the absence of the Leu9’Ser mutation.  Figure 4.4 shows the 
representative traces in the electrophysiological experiment.   
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Figure 4.4.  The representative traces in the electrophysiological experiment.  The red 
arrow indicates the application of 100 µM MTSET by pipette tip.  The red bar indicates 
the application of 10 µM TMB-8. A. Mutant receptor with cysteine at α198 and Leu9’Ser 
mutation in β subunit.  B. Mutant receptor with cysteine at α198 only.  
 
As we can see, MTSET-modification of the mutant nAChR with cysteine at α198 
resulted in a large inward current that could be reversibly inhibited by TMB-8, which 
indicated a constitutively active receptor.  This constitutive activity was seen for mutant 
receptor with or without the Leu9’Ser mutation.  However, the resulting inward current 
for the mutant with the Leu9’Ser mutation was about 10 times larger than that without it 
(Figure 4.5).  On one hand, these results confirmed the results seen by Cohen and 
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coworkers.  On the other hand, it suggested that incorporation of MTSET-modified 
cysteine into nAChR by nonsense suppression would not result in significant activation 
unless in the presence of the Leu9’Ser mutation due to the relatively low expression level 
of the receptor. 
 
Figure 4.5.  The inward current resulted from the MTSET-modification of the mutant 
nAChR with cysteine at α198 in the presence or absence of the Leu9’Ser mutation in β 
subunit. 
 
 In conclusion, we were not able to prepare a short tethered agonist, MTSET-
modified cysteine, nor the dCA-amino acid, due to the strong tendency toward the 
hydrolysis of these compounds.  Incorporation of a cysteine residue by nonsense 
suppression followed by chemical modification with MTSET resulted in constitutively 
active receptors.  However, the strong activity was only observed in the presence of 
Leu9’Ser mutation, suggesting that the effectiveness of the tethered agonist was limited 
by the relatively low expression of receptors by in vivo nonsense suppression 
methodology.  
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Chapter 5 
 
 
Methods in Molecular Biology, Electrophysiology and 
Molecular Docking, and Synthesis of Amino Acids 
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5.1  Methods in Molecular Biology and Electrophysiology 
 
Mutagenesis and mRNA Synthesis 
 
The site-directed mutagenesis of the nAChR TAG mutants was carried out using 
the QuikChange kit (Stratagene, La Jolla, CA).  The α, β, γ and δ subunits of nAChR 
were subcloned into the expression vector pAMV, which is optimized for oocyte 
expression (1).  The cDNA plasmid was linearized with NotI, and mRNA was prepared 
by in vitro transcription of the linearized cDNA plasmid using the Ambion (Austin, TX) 
mMESSAGE mMACHINE T7 Kit.  
  
tRNA Synthesis and Ligation of dCA-Amino Acid to tRNA 
 
The gene construction of the Tetrahymena thermophila tRNAGln CUA having a G 
at position 73 (THG73) has been described previously (1, 2).  The gene contains an 
upstream T7 RNA polymerase promoter and a downstream FokI restriction site.  
Template DNA for in vitro transcription of tRNA lacking the 3’-terminal bases C75 and 
A76 was prepared by linearizing pTHG73 with FokI.  In vitro transcription of the 
linearized plasmid was performed using the Ambion (Austin, TX) MEGAshortscript T7 
kit.  The α-NH2-protected dCA-amino acid or dCA was enzymatically ligated to the 
THG73 FokI runoff transcripts using T4 RNA ligase to form a full-length aminoacyl-
THG73 or a full-length but unacylated THG73-dCA as described previously (1).   
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Oocyte Microinjection 
 
Oocytes were removed from Xenopus laevis as described (3) and maintained at 
18°C, in ND96 solution (pH 7.5 adjusted by NaOH), which contains 96 mM NaCl, 2 mM 
KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, 2.5 mM sodium pyruvate, 0.5 mM 
theophyline and 10 µg/ml Gentamycin.  Before microinjection, the NVOC-aminoacyl-
tRNA was deprotected by irradiating the sample for 5 minutes with a 1000 W xenon arc 
lamp (Oriel) operating at 400 W equipped with WG-335 and UG-11 filters (Schott, 
Duryea, PA).  The deprotected aminoacyl-tRNA was immediately mixed with the desired 
mRNA and microinjected into Xenopus oocytes.  Each oocyte was injected with 50 nl of 
a 1:1 (volume) mixture of deprotected aminoacyl-tRNA (25-50 ng) and mRNA (12.5–18 
ng of total at a concentration ratio of 20:1:1:1 for αTAG:β:γ:δ or 2:1:10:10 for 
α:β:γTAG:δTAG).  Since the presence of constitutively active channels would be 
expected to compromise the health of the oocytes through a large leak current, 2µM - 
5µM TMB-8 (RBI, Natick, MA) was added to the incubation solution to block any leak 
current that might occur through the nAChR.  
 
It is worth mentioning that TMB-8 may have the effect of preventing the receptor 
from desensitization.  In our last experiments, when we were recording from oocytes 
expressing the mutant receptor with Tyr-O3Q at αTrp 149, we noticed that the standing 
current was initially small but continuously increased upon application of TMB-8, and 
the blocked current by TMB-8 also increased at the same scale and thus could reach the 
same plateau independent of the increasing standing current.  This observation suggested 
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that the receptor was rescued from desensitization by treatment with TMB-8.  This is 
consistent with the fact that we didn’t add TMB-8 in the oocyte incubation media in these 
last experiments, while in our earlier experiments we incubated the oocytes in ND96 with 
TMB-8, and the oocytes showed large standing currents. 
 
Electrophysiology 
 
Electrophysiological recordings were carried out 24-48 hours after injection. 
Whole-cell currents from oocytes were measured using a Geneclamp 500 amplifier and 
pCLAMP software (Axon Instruments, Foster City, CA) in the two-electrode voltage-
clamp configuration.  The first electrode simply measures the electrical potential across 
the oocyte’s membrane.  Using a feedback loop, current is injected via the second 
electrode to maintain the transmembrane potential at any desired value (that is, the 
membrane potential is “clamped” to the chosen value).  Microelectrodes were filled with 
3 M KCl and had resistances ranging from 0.5 to 1.5 MΩ.  Oocytes were continuously 
perfused with a nominally calcium-free bath solution consisting of 96 mM NaCl, 2 mM 
KCl, 1 mM MgCl2, and 5 mM HEPES (pH 7.5), while impaled with two electrodes.  
Microscopic ACh-induced and TMB-8-blocked currents were recorded in response to 
bath application of ACh and TMB-8 at the desired concentration at a holding potential of 
-80 mV.  All numerical and plotted data are from measurements obtained from 4-8 
oocytes and are reported as mean ± standard error.  Individual dose-response relations 
were fit to the Hill equation, I/Imax = 1/[1 + (EC50/[A])nH], where I is the current for the 
agonist concentration [A], Imax is the maximal current, EC50 is the concentration to elicit a 
 97
half-maximal response, and nH is the Hill coefficient.  
 
Bungarotoxin Binding and Western Blot Analysis 
 
125I-α-bungarotoxin binding experiments were performed as described (4). 
Oocytes were incubated in 400 µl of calcium-free ND96 solution containing 10 mg/ml 
BSA (Sigma) for 10 minutes and then 125I-α-bungarotoxin (Amersham) was added to a 
final concentration of 1 nM.  After incubation for 2 hours, the oocytes were washed 
extensively and then counted in a Beckman LS5000 γ-counter.  
 
Western blot analyses were carried out as described (5).  A hemagglutinin (HA) 
epitope was subcloned into the intracellular loop between the third and fourth 
transmembrane domains of the α subunit.  The vitelline/plasma membranes were 
manually stripped from oocytes expressing nAChR (6).  Alternatively, the oocytes were 
treated with sulfo-NHS-LC-biotin (Pierce) and then homogenized.  After removing the 
yolks of the oocytes by centrifuge, the remaining supernatant was incubated with 
streptavidin-agarose beads (Sigma).  The protein was then eluted from the beads by 
adding SDS buffer.  In either case, the samples were analyzed by SDS-PAGE, followed 
by immunoblotting with the anti-hemagglutinin antibody (BabCO, cat # MMS-101R), 
and visualized using an ECL detection kit (Amersham).  
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5.2. Methods for Molecular Docking 
 
Structure Preparation 
 
The coordinates of the AChBP crystal structure were downloaded from the 
Protein Data Bank (pdb id: 1I9B).  Hydrogens were added to the protein using Biograf.  
The whole protein including the HEPES ligands was then minimized using MPSim (7) 
with the Dreiding force field (8).  The CMM nonbond method (9) was used to allow 
efficient yet fast energy evaluation.  The surface generalized Born (SGB) implicit 
solvation model (10) was applied to simulate the solvation effect of the bulk solvent.  
Protein was described using CHARMM22 (11) charges, with counterions (Na+ and Cl-) 
added to neutralize charged residues.  The final structure after minimization was used in 
the docking simulation. 
 
For the HEPES and acetylcholine ligands, Mullikan charges based on molecular 
orbitals from quantum mechanics were used.  The quantum mechanics calculations were 
done using Jaguar 4.0 (Schrödinger Inc, Portland, OR) at the HF level with the 6-31G ** 
base set.  The geometry was optimized by using forces calculated with Poisson 
Boltzmann continuum solvation (12). 
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Docking Protocol 
 
The HierDock protocol (13) was used in docking acetylcholine into the binding 
site of AChBP.  It is based on DOCK 4.0 (14), and has been used in screening of 
unnatural amino acids binding to aminoacyl-tRNA synthetases (15) and odor ligands 
binding to olfactory receptors  (13).  The HierDock protocol combines the fast Monte 
Carlo conformation search and a good force field scoring function with solvation to 
accurately get the binding conformation of a ligand in a receptor.  It has a procedure for 
screening a binding site if that information is unknown for a certain ligand to the 
receptor.  Because the acetylcholine binding site is well known in this case, the binding 
site screening procedure has been skipped.  The rest of the procedures are: 
 
(1) A negative image of the receptor’s Connolly molecular surface in the binding site 
was generated and filled with a set of overlapping spheres.  A probe radius of 1.4 Å and a 
surface density of 5 dots/Å2 were used.  The binding site was defined as the cube 
occupied by the HEPES ligand in the crystal structure plus a 5 Å margin in each 
dimension.  An energy grid was then generated for the binding region plus a 10 Å margin 
for each dimension.  This energy grid was used later to evaluate ligand conformations 
and orientations. 
 
(2) Ligand conformations were generated using a Monte Carlo procedure and 
matched to spheres in the binding site.  The total number of conformations was set to 
5000.  Each conformation was then passed through a bump filter.  A bump was defined as 
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an overlap of two atoms between ligand and receptor with distance lass than 75% of the 
combined van der Waals value.  Conformations with more than three bumps were 
rejected without further evaluation.  The ligand conformation was then minimized and 
the binding energy was calculated using the energy grid.  The top 50 conformations with 
the best binding energies were saved for further evaluation.  These steps were done using 
DOCK version 4.0 (14). 
 
(3) DOCK is considered a coarse grain search procedure because it lacks precision in 
conformation evaluation.  A subsequent fine grain binding energy calculation was done 
using MPSim, a full molecular mechanics and molecular dynamics suite with full force 
field capability.  First each of the 50 conformations out of DOCK was minimized in the 
presence of the receptor.  The 5 conformations with the lowest energies were selected to 
run 5 cycles of annealing dynamics to get better binding interaction between the ligand 
and receptor.  Each cycle of annealing dynamics consisted of heating the system from 50 
K to 600K and cooling from 600K to 50K in steps of 20K for 0.5 ps.  These annealing 
MD calculations included the SGB continuum solvation with a dielectric constant of 80 
and a solvent radius of 1.4 Å.  Each cycle of annealing dynamics generated a minimized 
ligand conformation, thus totally 25 conformations were generated and the one with the 
lowest energy was selected to be the docked ligand conformation.  The binding energy 
was calculated using the following definition: 
complexreceptorligandbinding GGGG ∆−∆+∆=∆∆− )( , 
where ∆Gcomplex  is the total energy of the protein with the ligand bound in this case being 
AChBP with ACh bound to it including solvation, ∆Gligand  and ∆Greceptor are the energies 
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of the ligand and receptor including solvation. The receptor and the ligand structures 
were optimized in Molecular Dynamics with SGB solvation.  
 
5.3.  Synthesis of Amino Acids and dCA-Amino Acids 
 
Materials 
 
Reagents were purchased from Aldrich, Sigma, or other commercial sources. 
Anhydrous THF was distilled from sodium benzophenone; anhydrous methylene 
chloride, toluene and acetonitrile were distilled from CaH2; anhydrous acetone was 
distilled from CaSO4; anhydrous DMF was obtained from Fluka.  BakerDRY solvents 
(ultra low water) in CYCLE-TAINER from J. T. Baker were also used for anhydrous 
THF, methylene chloride, ethyl ether and acetonitrile.  Flash chromatography was on 
230-400 mesh silica gel with the solvent indicated.  All NMR shifts are reported as δ ppm 
downfield from TMS.  1H NMR spectras were recorded at 300 MHz in CDCl3 using a GE 
QE-300 or Varian 300 spectrometer.  FAB-MS determinations were performed at the 
University of Nebraska, Lincoln.  Electrospray ionization (ESI), quadruple mass 
spectrometry was performed at the Caltech Protein/Peptide Micro Analytical Laboratory.  
High performance liquid chromatography (HPLC) separations were performed on a 
Waters dual 510 pump liquid chromatography system equipped with a Waters 490E 
variable wavelength UV detector for semi-preparative HPLC and a Waters 996 PDA 
(photodiode array) UV detector for analytical HPLC.  Waters Prep Nova-Pak HR C18 
column (7.8x300 mm) was used for semi-preparative HPLC and Waters Nova-Pak C18 
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column (3.9x150 mm) was used for analytical HPLC.   Nitroveratryloxycarbonyl chloride 
(NVOC-Cl) and NVOC-Tyrosine t-butyl ester were prepared as described earlier (16).  
 
General Procedure for Coupling of Amino Acid to dCA 
  
This method is essentially as described (16, 17).  The N-protected amino acid 
cyanomethyl ester (~30 µmol, 3 equivalents) was mixed with the tetrabutylammonium 
salt of the dCA dinucleotide (~10 µmol, 1 equivalent) in 400 µl of dry DMF.  The 
reaction mixture was kept stirring for 1-3 hours under argon.  The reaction was monitored 
by reverse phase analytical HPLC with a gradient from 25 mM ammonium acetate (pH 
4.5) to CH3CN.  The crude product was isolated using reverse-phase semi-preparative 
HPLC.  The desired fractions containing the aminoacyl dinucleotide were combined, 
frozen, and lyophilized.  The lyophilized solid was redissolved in 10 mM aqueous acetic 
acid/acetonitrile and lyophilized a second time to remove ammonium ions, which inhibits 
T4 RNA ligase in the ligation of dCA-amino acid to the tRNA.  The products were 
characterized by mass spectrometry and quantified by UV/Vis spectra, assuming ε350 
~6350 per nitroveratryl group. 
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Scheme 5.1.  Synthesis of dCA-amino acid.  
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dCA-NVOC-O-2-(trimethylammonium)ethyl tyrosine (dCA-NVOC-Tyr-O2Q).  
Prepared as above using NVOC-O-2-(trimethylammonium)ethyl tyrosine cyanomethyl 
ester (3a) as starting material.  FAB-MS: [M+], calc'd for C43H56N11O21P2: 1124.3128; 
found: 1124.2. 
 
dCA-NVOC-O-4-(trimethylammonium)butyl tyrosine (dCA-NVOC-Tyr-O4Q).  
Prepared as above using NVOC-O-4-(trimethylammonium)butyl tyrosine cyanomethyl 
ester (3b) as starting material.  FAB-MS: [M+], calc'd for C45H60N11O21P2: 1152.3440; 
found: 1152.3. 
 
dCA-NVOC-O-5-(trimethylammonium)pentyl tyrosine (dCA-NVOC-Tyr-O5Q).  
Prepared as above using NVOC-O-5-(trimethylammonium)pentyl tyrosine cyanomethyl 
ester (3c) as starting material.  FAB-MS: [M+], calc'd for C46H62N11O21P2: 1166.3596; 
found: 1166.4. 
 
dCA-Nα, N5(in)-di-NVOC-5-amino tryptophan.  Prepared as above using Nα, N5(in)-di-
NVOC-5-amino tryptophan cyanomethyl ester (8) as starting material.  FAB-MS: calc'd 
for C50H55N13O26P2: 1316.0114; found [M-H]–: 1314.2. 
 
dCA-N-NVOC-S-trityl cysteine.  Prepared as above using N-NVOC-S-trityl cysteine 
cyanomethyl ester as starting material.  ESI-MS: calc'd for C51H54N10O20P2S: 1221.0626; 
found [M-H]–: 1219.4, [M-2H]2–: 609.2. 
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Synthsis of Tyr-OnQ 
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Scheme 5.2.  Synthesis of Tyr-OnQ. 
 
NVOC-O-(2-bromoethyl) tyrosine t-butyl ester (1a).  To a mixture of 0.690 ml (8 
mmol, 16 equivalents) of 1, 2-dibromoethane and 330 mg (1 mmol, 2 equivalents) of 
Cs2CO3 in 15 ml of anhydrous DMF was added a solution of 238 mg (0.5 mmol) of 
NVOC-tyrosine t-butyl ester in 10 ml of DMF slowly over 10 hours using a syringe 
pump.  After stirring overnight, the reaction mixture was quenched by adding 30 ml of 
water and extracted by 3 x 30 ml of ethyl acetate.  The combined organic layers were 
washed with water once, dried (over Na2SO4), rotary-evaporated, and chromatographed 
(30:70 ethyl acetate:petroleum ether), providing 61 mg (21%) of product.  1H NMR 
(CDCl3) δ 7.69 (s, 1H), 7.05 (d, 2H), 6.95 (s, 1H), 6.81 (d, 2H), 5.54 and 5.46 (AB, 1H), 
5.32 (d, 1H), 4.48 (m, 1H), 4.24 (t, 2H), 3.93 (s, 6H), 3.61 (t, 2H), 3.03 (m, 2H), 1.41 (s, 
9H). 
 
NVOC-O-(4-bromobutyl) tyrosine t-butyl ester (1b).  This compound was prepared by 
the procedure described above except using 1, 4-dibromobutane as starting material. 
 105
Yield 67%.  1H NMR (CDCl3) δ 7.68 (s, 1H), 7.06 (d, 2H), 6.94 (s, 1H), 6.77 (d, 2H), 
5.53 and 5.45 (AB, 1H), 5.35 (d, 1H), 4.46 (m, 1H), 3.94 (m, 2H), 3.92 (s, 6H), 3.46 (t, 
2H), 3.01 (m, 2H), 2.02 (m, 2H), 1.90 (m, 2H), 1.40 (s, 9H).   
 
NVOC-O-(5-bromopentyl) tyrosine t-butyl ester (1c).  This compound was prepared 
by the procedure described above except using 1, 5-dibromopentane as starting material. 
Yield 58%.  1H NMR (CDCl3) δ 7.52 (s, 1H), 6.94 (d, 2H), 6.82 (s, 1H), 6.65 (d, 2H), 
5.61 (d, 1H), 5.32 (m, 2H), 4.35 (m, 1H), 3.96 (m, 2H), 3.77 (s, 6H), 3.28 (t, 2H), 2.91 
(m, 2H), 1.77 (m, 2H), 1.65 (m, 2H), 1.40 (m, 2H), 1.27 (s, 9H). 
 
NVOC-O-(4-Bromobutyl) tyrosine cyanomethyl ester (2b).  To a solution of 290 mg 
(0.48 mmol) of azeotropically dried (with toluene) 1b in 1.7 ml of dry CH2Cl2 was slowly 
added 2.8 ml of TFA (37.2mmol, 77.5 equivalents).  The mixture was stirred under argon 
at room temperature for two hours.  TFA was removed by passing argon through the 
reaction solution.  The residue was rotary-evaporated with toluene twice (2x10 ml), dried 
under vacuum and then used directly in the next step.  To this crude product was added 5 
ml of anhydrous DMF, 0.67 ml (10.5 mmol, 21.8 equivalents) of chloroacetonitrile and 
96 µL of diisopropylethylamine.  The mixture was stirred at room temperature overnight. 
After about 14 hours the reaction was quenched by adding 10 ml of 0.1 M KH2PO4 and 
10 ml of water and then extracted with 2x50 ml of ethyl acetate.  The combined organic 
layers were washed with water, dried (over Na2SO4) and rotary-evaporated.  Flash 
chromatography (1:3 to 2:3 ethyl acetate:petroleum ether) gave 210 mg (74%) of product. 
1H NMR (CDCl3) δ 7.66 (s,1H), 7.03 (d, 2H), 6.89 (s,1H), 6.80 (d, 2H), 5.51 and 5.41 
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(AB, 1H), 5.38 (d, 1H), 4.72 (m, 3H), 3.94 (m, 2H), 3.91 (s, 6H), 3.58 (t, 1H), 3.45 (t, 
1H), 3.07 (m, 2H), 2.01 (m, 2H), 1.92(m, 2H). 
 
NVOC-O-(2-Bromoethyl) tyrosine cyanomethyl ester (2a).  This compound was 
prepared by the procedure described above using 1a as starting material. Yield 58%.  1H 
NMR (CDCl3) δ 7.70 (s, 1H), 7.07 (d, 2H), 6.92 (s, 1H), 6.87 (d, 2H), 5.56 and 5.45 (AB, 
1H), 5.29 (d, 1H), 4.76 (m, 3H), 4.27 (t, 2H), 3.95 (s, 6H), 3.63 (t, 2H), 3.10 (m, 2H). 
 
 NVOC-O-(5-Bromopentyl) tyrosine cyanomethyl ester (2c).  This compound was 
prepared by the procedure described above using 1c as starting material. Yield 69%. 1H 
NMR (CDCl3) δ 7.61 (s, 1H), 7.01 (d, 2H), 6.86 (s, 1H), 6.77 (d, 2H), 5.53 (d, 1H), 5.46 
and 5.37 (AB, 1H), 4.71 (m, 3H), 3.89 (m, 2H), 3.87 (s, 6H), 3.51 (t, 1H), 3.38 (t, 1H), 
3.05 (m, 2H), 1.87 (m, 2H), 1.75 (m, 2H), 1.56 (m, 2H). 
 
NVOC-O-4-(trimethylammonium)butyl tyrosine cyanomethyl ester (NVOC-Tyr-
O4Q) (3b).  200 mg (0.337 mmol) of 2b was mixed with 650 mg (4.333 mmol, 12.5 
equivalents) of sodium iodide in 10 ml of acetone at room temperature.  The reaction was 
kept stirring in the dark overnight.  Acetone was then rotary-evaporated off, and the solid 
was partitioned between water and methylene chloride (30 ml each).  The aqueous layer 
was extracted with methylene chloride once.  Organic layers were combined, washed 
with water once, dried (over Na2SO4), and rotary-evaporated to give 200 mg (93%) of 
yellowish solid NVOC-O-(4-iodobutyl) tyrosine cyanomethyl ester.  Half of this product 
was carried on to make 3b.  The solution of the iodide in 7 ml of dry toluene and 12 ml of 
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dry THF was cooled to 0 °C in an ice/NaCl bath.  Then trimethylamine was passed 
through the solution via a metal needle for about 5 minutes.  The solution was allowed to 
warm up to room temperature and stirred in the dark for 32 hours.  Precipitate formed on 
the inner wall of the flask.  Argon was passed through to get rid of the amine, which was 
trapped by 6 N HCl.  When most of the amine was removed (indicated as neutral by wet 
pH paper), the solution was decanted and the solid was rinsed with ethyl acetate three 
times and dried under vacuum.  Yield 70 mg (68%).  1H NMR (CDCl3) δ 7.74 (s,1H), 
7.23 (d, 2H),  7.13 (s,1H), 6.91 (d, 2H), 6.46 (d 1H), 5.46 and 5.39 (AB, 1H),  4.85 (s, 
2H),  4.52 (m, 1H),  4.05 (t, 2H),  3.96 (s, 3H),  3.93 (s, 3H),  3.39 (m, 2H),  3.10 (s, 9H), 
3.00 (m, 2H), 1.98 (m, 2H),  1.85 (m, 2H). 
 
NVOC-O-2-(trimethylammonium)ethyl tyrosine cyanomethyl ester (NVOC-Tyr-
O2Q) (3a).  This compound was prepared by the procedure described above using 2a as 
starting material.  Yield 85%.  1H NMR (CDCl3) δ 7.73 (s, 1H), 7.26 (d, 2H), 7.11 (s, 
1H), 6.94 (d, 2H), 6.41 (d, 1H), 5.44 and 5.37 (AB, 1H), 4.83 (s, 2H), 4.55 (m, 1H), 4.41 
(m, 2H), 3.95 (s, 3H), 3.92 (s, 3H), 3.74 (m, 2H), 3.20 (s, 9H), 3.01 (m, 2H). 
 
NVOC-O-5-(trimethylammonium)pentyl tyrosine cyanomethyl ester (NVOC-Tyr-
O5Q) (3c).  This compound was prepared by the procedure described above using 2c as 
starting material.  Yield 74%.  1H NMR (CDCl3) δ 7.72 (s, 1H), 7.20 (d, 2H), 7.11 (s, 
1H), 6.87 (d, 2H), 6.47 (d, 1H), 5.44 and 5.37 (AB, 1H), 4.83 (s, 2H), 4.51 (m, 1H), 4.00 
(t, 2H), 3.92 (s, 3H), 3.90 (s, 3H), 3.31 (m, 2H), 3.13 (m, 2H), 3.08 (s, 9H), 1.98 (m, 2H), 
1.83 (m, 2H), 1.53 (m, 2H). 
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Synthesis of 5-Amino Tryptophan 
 
 Besides the tryptophan analogs with electron-withdrawing groups discussed in 
Chapter 2, we also made 5-amino tryptophan as one with an electron-donating group.  
The synthetic strategy (Scheme 5.3) was based on the method developed by Roberts and 
coworkers (18).  We have used this route previously to make many tryptophan analogs 
(19).  This strategy simplified the synthesis of tryptophan analogs to the synthesis of the 
corresponding indole derivatives.  
 
Br OCH2CH3
O
N
OH
K2CO3, CH2Cl2 N
H
BOC-HN
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N
OH
N
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Scheme 5.3.  Synthesis of 5-amino tryptophan. 
 
5-(tert-butoxycarbonylamino)indole (4).  A heterogeneous solution of 1.0 g of 5-amino 
indole in 15 ml of dry THF was stirred for 15 minutes before 1.816 g (1.1 eq) of Di-tert-
butyl dicarbonate (taken from refrigerator right before weighing) was added.  The 
mixture was stirred for one and an half hours before it was quenched with 15 ml of 
saturated NaCl.  The aqueous layer was extracted with 20 ml of THF twice and the 
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organic layers were combined, washed with saturated NaCl, dried over Na2SO4 and 
rotary-evaporated.  Flash chromatography (ethyl acetate: petroleum ether 1:3) gave 1.188 
g (68%) of product.  1H NMR (CDCl3) δ 1.56 (s, 9H), 6.49 (s, 1H), 6.51 (t, 1H), 7.14 (d, 
1H), 7.21 (t, 1H), 7.35 (d, 1H), 7.72 (s, 1H), 8.14 (s, 1H). 
 
5-(tert-butoxycarbonylamino)-α-hydroxyimino-tryptophan ethyl ester (5).  To a 
solution of 129 mg (1eq) of ethyl 3-bromo-2-hydroxyimino-propanoate (19) and 494 mg 
(3.5 eq) of 4 in 6 ml of dry CH2Cl2 was added 98 mg of anhydrous Na2CO3.  The reaction 
was kept stirring for 2 hours before it was quenched by 10 ml of CH2Cl2 and 10 ml of 
H2O.  The aqueous layer was extracted with CH2Cl2.  The organic layers were combined, 
washed with H2O, dried over Na2SO4 and rotary-evaporated to give a white solid.  Flash 
chromatography (ethyl acetate: petroleum ether 1:1) gave 118 mg (53%) of product.  1H 
NMR (CDCl3) δ 1.28 (t, 3H), 1.51 (s, 9H), 4.04 (s, 2H), 4.24 (q, 2H), 6.50 (s, 1H), 7.08 
(d, 1H), 7.22 (d, 1H), 7.24 (d, 1H), 7.72 (s, 1H), 7.96 (b, 1H), 8.85 (s, 1H).  
 
5-(tert-butoxycarbonylamino) tryptophan ethyl ester (6).  To a 25 ml flask containing 
118 mg of 5 was added 9 ml of THF and 1 ml of H2O.  Two aluminum pellets were 
weighed (778 mg), treated with 8% NaOH for 3 minutes, rinsed with water and then 
treated with 2% HgCl2 for 5 minutes.  The pellets were then added to the solution of 5.  
Gray precipitate appeared gradually.  The reaction was kept stirring overnight and then 
15 ml of THF was added.  The mixture was filtered and the filtrate was dried over 
Na2SO4 and rotary-evaporated to give light yellow sticky oil.  Yield (83%).  1H NMR 
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(CDCl3) δ 1.24 (t, 3H), 1.51 (s, 9H), 3.01 (dd, 1H), 3.20 (dd, 1H), 3.73 (m, 3H), 4.15 (q, 
2H), 6.48 (b, 1H), 7.02 (s, 1H), 7.13 (d, 1H), 7.23 (d, 1H), 7.61 (s, 1H), 8.08 (s, 1H). 
 
Nα, N5(in)-di-NVOC-5-amino tryptophan ethyl ester (7).  To a 10 ml flask containing 
86 mg of 6 was added 1 ml of dry CH2Cl2 and 102 mg of p-dimethoxybenzene, followed 
by 1 ml of TFA.  After stirring at room temperature for 1hour, argon was bubbled 
through the flask to remove CH2Cl2 and TFA and a sticky solid was obtained.  2 ml of 
CH2Cl2 was added and the solution was rotary-evaporated.  Then 1 ml of toluene was 
added and the mixture was vacuum pumped for a few hours to yield an orange-brown 
sticky solid which was reacted with NVOC-Cl using the standard procedure.  120 mg 
(67%) of product was obtained.  1H NMR (CDCl3) δ 1.23 (t, 3H), 3.31 (m, 2H), 3.87, 
3.94 and 3.98 (s, 12H), 4.17 (m, 2H), 4.72 (q, 1H), 5.50 (s, 2H), 5.59 (s, 2H), 5.40 (d, 
1H), 6.92 (s, 1H), 7.03 (s, 1H), 7.10 (d, 1H), 7.26 (d, 1H), 7.60 (s, 1H), 7.69 (s, 2H), 7.73 
(s, 1H), 8.07 (s, 1H).  
 
Nα, N5(in)-di-NVOC-5-amino tryptophan cyanomethyl ester (8).  To a 25 ml flask 
containing 120 mg of 7 was added 10 ml of dioxane and 2 ml of H2O, followed by 1ml of 
1N NaOH.  After stirring for 4 hours, the reaction was stopped. 30 ml of CH2Cl2, 10 ml 
of 1M KH2PO4 (pH 4) and 20 ml of H2O were added.  The aqueous layer was separated 
and adjusted to pH 4 with KH2PO4.  Aqueous layer was extracted with 20 ml of CH2Cl2.  
The organic layers were combined, washed with H2O, dried over Na2SO4 and rotary-
evaporated.  The crude product was used directly to prepare the cyanomethyl ester using 
the standard procedure.  Yield 42%.  1H NMR (CDCl3) δ 3.32 (m, 2H), 3.90, 3.93 and 
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3.95 (s, 12H), 4.65 (b, 1H), 4.70 (m, 1H), 4.84 (m, 1H), 5.37 (d, 2H), 5.48 (d, 2H), 5.59 
(s, 2H), 6.91 (s, 1H), 7.08 (s, 1H), 7.10 (d, 1H), 7.32 (d, 1H), 7.60 (s, 1H), 7.68 (s, 2H), 
7.72 (s, 1H), 8.12 (s, 1H). 
 
Synthesis of MTSET-Modified Cysteine 
  
N-NVOC-S-trityl cysteine.  This compound was prepared from S-trityl cysteine and 
NVOC-Cl using the standard procedure.  Yield 58%.  1H NMR (acetone-d6) δ 2.70 (m, 
2H), 3.86 (s, 3H), 3.93 (s, 3H), 4.16 (m, 1H), 5.46 (s, 2H), 6.98 (d, 1H), 7.19 (s, 1H), 7.35 
(m, 15H), 7.71 (s, 1H). 
 
N-NVOC-S-trityl cysteine cyanomethyl ester.  This compound was prepared from N-
NVOC-S-trityl cysteine and chloroacetonitrile using the standard procedure.  Yield 88%.  
1H NMR (acetone-d6) δ 2.65 (dd, 2H), 3.90 (s, 3H), 3.94 (s, 3H), 4.13 (m, 1H), 4.93 (s, 
2H), 5.47 (s, 2H), 7.18 (s, 1H), 7.25-7.44 (m, 15H), 7.73 (s, 1H). 
 
N-NVOC-cysteine cyanomethyl ester.  The deprotection of the trityl group was carried 
out using a procedure reported by Pearson et al (20).  To a 50 ml flask containing 600 mg 
of N-NVOC-S-trityl cysteine cyanomethyl ester was added 3 ml of CH2Cl2, 0.6 ml (4 eq) 
of triethylsilane and 1.5 ml (20 eq) of TFA.  The reaction mixture turned green yellow 
right away and was stirred for 50 minutes.  Argon was passed through to remove TFA.  
CH2Cl2 was added and then rotary-evaporated and vacuum pumped.  Flash 
chromatography (30:70 ethyl acetate: petroleum ether) gave 78% product.  1H NMR 
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(CDCl3) δ 1.47 (t, 1H), 3.06 (m, 2H), 3.96 (s, 3H), 4.01 (s, 3H), 4.80 (m, 3H), 5.51 and 
5.60 (AB, 2H), 5.75 (d, 1H), 7.01 (s, 1H), 7.72 (s, 1H).   
 
N-NVOC-cysteine.  This compound was prepared as above using N-NVOC-S-trityl 
cysteine as starting material.  Yield 96%.  1H NMR (CD3CN) δ 1.85 (t, 1H), 2.97 (m, 
2H), 3.91 (s, 3H), 3.97 (s, 3H), 4.44 (m, 1H), 5.46 (s, 2H), 7.17 (s, 1H), 7.72 (s, 1H). 
 
N-NVOC-S-(2-trimethylammonium)ethylthio cysteine.  To a 5 ml flask was added 35 
mg of N-NVOC-cysteine and 40 mg (1.5 eq) of MTSET followed by 2.5 ml of dry 
ethanol and 1 ml of dry acetonitrile.  TLC showed the reaction was complete after 10 
minutes.  The reaction mixture was stirred for another 10 minutes and then frozen and 
lyophilized.  The yellow solid obtained was dissolved in ~1:1 H2O:acetonitrile in portions 
right before HPLC injection.  The product was purified by semi-preparative HPLC, 
eluting with a gradient of from 25 mM NH4OAc to acetonitrile and eluted at ~25% of 
acetonitrile.  The fractions were combined and lyophilized.  Yield 70%.  1H NMR (D2O) 
δ 2.83 (dd, 1H), 2.96 (s, 11H), 3.14 (dd, 1H), 3.48 (m, 2H), 3.71 (s, 3H), 3.77 (s, 3H), 
4.16 (q, 1H), 4.64 (s, 2H), 5.10 and 5.27 (AB, 2H), 6.88 (s, 1H), 7.51 (s, 1H).  ESI-MS: 
calc'd for C18H28N3O8S2: 478.57; found [M]+: 478.2. 
 
N-NVOC-S-(2-trimethylammonium)ethylthio cysteine cyanomethyl ester.  The 
reaction was run in a similar way as above except that ~1 eq of sodium ethoxide was also 
added.  The reaction was monitored by analytical HPLC with a gradient from 25 mM 
NH4OAc to acetonitrile.  The product was separated by semi-preparative HPLC but MS 
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and 1H NMR indicated a mixture of expected product and its hydrolyzed byproduct.  1H 
NMR (D2O) δ 3.15 (d or t).  ESI-MS: calc'd for C20H29N4O8S2: 517.606; found [M]+: 
517.2 and 478.2. 
 
4-N-o-Nitrophenyl sulfenyl-2’-deoxycytidylyl(3’-5’)adenosine-5’-phosphate (NPS-
dCA).  This compound was prepared according to the reported literature (21).  To a 25 
ml flask was added 192 mg of the tetrabutylammonium salt of dCA and 6ml of dry 
DMSO.  To this solution was added 3x44.3 mg (~4 eq) of o-nitrophenyl sulfenyl chloride 
and 3 x 33 µl (~4eq) of triethylamine at 0, 1.5 and 3 hours.  The reaction was quenched 
after 5 hours with a solution of 257 mg of NH4OAc in 2-3 ml of H2O and lyophilized to a 
yellow solid.  The product was purified by preparative HPLC, eluting with a gradient of 
0-40% acetonitrile in aqueous 25 mM NH4OAc.  The appropriate fractions were 
collected, combined and lyophilized.  Yield 48%.  1H NMR (500 MHz) (D2O) δ 1.88 (m, 
1H), 2.32 (m, 1H), 3.89 (s, 2H), 4.01 (m, 2H), 4.14 (s, 1H), 4.20 (s, 1H), 4.39 (t, 1H), 
4.55 (t, 1H), 5.85 (d, 1H), 5.96 (m, 1H), 6.11 (b, 1H), 7.08 (d, 2H), 4.34 (b, 1H), 7.78 (d, 
1H), 7.91 (s, 1H), 7.95 (b, 1H), 8.25 (s, 1H).  ESI-MS: calc'd for C25H29N9O15P2S: 
789.57; found [M-H]– 788.0 and [M-2H]2– 393.4. 
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